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Inhaled nebulized hypertonic saline (HTS) is a commonly prescribed mutation-agnostic 
therapy used in the treatment of CF-related lung disease. It is currently well-understood that HTS 
functions, in part, to increase the volume of airway surface liquid (ASL) by generating an osmotic 
gradient that draws water into the airway lumen and, thus, increasing mucociliary clearance 
(MCC). However, recent research has also demonstrated that HTS-triggered increase in ASL 
height is mediated by the nervous system, whereby HTS stimulates sensory neurons to promote 
active secretion of ASL via airway epithelia. It has been shown that there is an approximate 50% 
reduction in the effects of HTS on ASL height in the presence of neural blockers. To study how 
this relationship translates into potential differences in MCC, this thesis seeks to test whether 
neurogenic component of HTS influences HTS-triggered increase in MCC ex vivo in excised swine 
trachea. Using a MCC assay based on tracking the clearance of tantalum microdisks by the ciliated 
epithelium of the trachea, we were able to observe that the HTS-mediated increase in MCC is 
mostly eliminated following preincubation with the neural blocker tetrodotoxin (TTX) in wild-
type swine. To further demonstrate the utility of the nervous system in promoting MCC, we used 
sensory agonists capsaicin and menthol in combination with HTS or isotonic saline (ITS), and 
found them to cause substantial improvements on MCC in wild-type swine. Lastly, our 
experiments using CFTR-/- piglets demonstrated a surprising trend, whereby preincubation with 
TTX potentiated the effects of HTS, rather than decreasing them. We conclude that HTS-triggered 
increase in MCC is heavily dependent on the nervous system in swine. The next step will be to 
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Cystic fibrosis (CF) is the most common lethal chronic genetic disorder in Canada, with 1 in 
3600 Canadians born with the disease, and more than 70,000 patients worldwide (Cutting, 2015). 
Though the condition is fatal, recent advancements in both the diagnosis and treatment of the 
disease have improved the median age of survival for patients significantly. As of 2018, the 
estimated median age of survival for CF in Canada was 52.1 years (Cystic Fibrosis Canada, 2018), 
and 47.4 years in the United States (Cystic Fibrosis Foundation, 2018). The median age of 
Canadian CF patients listed in the 2018 Cystic Fibrosis Canada Patient Registry was 23.5 years, 
up from 11.7 years in 1987, further illustrating improvements in patient care (Cystic Fibrosis 
Canada, 2018).  
 
CF is caused by mutations in the gene encoding for the Cystic Fibrosis Transmembrane 
conductance Regulator (CFTR) anion channel, leading to progressive decline in the health of the 
patient (Regard et al., 2018). The primary organ system affected is the respiratory tract, but the 
presence of this channel across multiple organ systems means that CF may cause complications in 
numerous other organs as well (Cutting, 2015; Regard et al., 2018). While death typically results 
from respiratory complications, complications within the gastrointestinal tract, kidneys, pancreas, 
and other organs cause significant morbidity in patients, leading to severe complications if left 
untreated. With the availability of effective treatments for non-respiratory complications of the 
disease, research on CF has largely turned toward treating the effects in the respiratory tract (Davis, 
2006). CFTR mutations result in dehydration of the airway surface liquid layer which, 
consequently, impairs mucociliary clearance of inhaled particles, thus diminishing the innate 
defense against pathogenic organisms. In turn, this causes the mucus accumulation and subsequent 
airway obstruction that is characteristic of CF (Kreda et al., 2012). Thus, there has been an interest 
in developing therapies aimed at restoring the airway hydration. One such treatment is nebulized 
hypertonic saline (HTS), aimed at improving airway hydration and increasing mucociliary 
clearance, which will be the focus of this thesis.  
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HTS nebulization has been shown to improve mucociliary clearance and the beneficial effects 
on lung health through airway rehydration is undisputed (Elkins et al., 2006; Tildy & Rogers, 
2015). However, its beneficial effect on lung function, as measured by spirometry, can be small 
and the treatment is not always tolerated by patients; thus there is a need for improved rehydration 
treatments. Unfortunately, the mechanisms of action of HTS nebulization remain somewhat 
unclear. Due to these knowledge gaps, it is difficult to improve upon the current treatment to 
increase its effectiveness and tolerability. Traditionally, HTS nebulization was believed to increase 
airway hydration through an osmotic effect, which would draw water from the tissue into the lumen 
of the airway. Recent experiments have shown that, in addition to the osmotic effect, HTS-
triggered increase in airway hydration is partially mediated by stimulation of sensory neurons in 
the airway, which stimulate active fluid secretion by the airway epithelia. Thus, the effect of HTS 
on airway hydration is partially blocked in the presence of neural blockers lidocaine, tetrodotoxin, 
and atropine (Luan et al., 2019).  
 
In this thesis, I seek to test the hypothesis that HTS-triggered increase in mucociliary clearance 
are also mediated by stimulation of the nervous system. This research will provide an improved 
understanding of HTS at a basic scientific level, while also informing potential novel therapies or 
modifications to improve existing therapies.  
 
1.2 Genetic Basis of Cystic Fibrosis 
 
 CF is an autosomal recessive disorder, caused by a variety of mutations in the CFTR gene 
located on chromosome 7 in humans (Rommens et al., 1989). The gene encodes the CFTR anion 
channel, a member of the ATP-binding cassette transmembrane superfamily. This protein consists 
of six alpha-helices, a regulatory domain, two membrane-spanning regions, two cytoplasmic 
domains, and multiple phosphorylation consensus sequences (Farkas et al., 2020; Higgins, 1992). 
The CFTR protein embeds in the lipid membrane of epithelial cells in multiple organs, where it 
plays a major role in ion and water balance (Farkas et al., 2020; Riordan et al., 1989). Primarily, it 
is responsible for transporting chloride and bicarbonate anions across the apical membrane of 
multiple cell types, including those of the epithelial cells lining the airways (Denning et al., 1992; 
Trezíse & Buchwald, 1991).  
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Roughly 2000 disease-causing CFTR gene mutations have been described to date, and can 
be classified with respect to their effect on protein structure and function (Cutting, 2015). One 
commonly cited expanded classification system places mutations of the CFTR gene into six 
distinct classes, organized with respect to their effect on the CFTR protein production and function. 
Class I mutations involve mutations to the protein production, arising from nonsense mutations 
predominately, as well as frameshift and splicing mutations. These mutations prevent the 
messenger RNA from being properly translated, thus leading to severely reduced or completely 
absent expression of the CFTR protein (Veit et al., 2016). Class II mutations include the most 
common mutation, a deletion of a phenylalanine in position 508 (i.e., F508del), which affects more 
than 70% of CF patients (Gentzsch & Mall, 2018). Class II mutations result in misfolding, 
premature degradation, and impaired protein production. These result in an inability for the protein 
to properly reach the cell surface (Marson et al., 2016; Veit et al., 2016), thus impairing function. 
Class III mutations are characterized by impaired CFTR channel regulation due to abnormal gating 
properties; in such mutations, there is a reduction in the open probability of the channel (Veit et 
al., 2016). Class IV mutations lead to reduced channel conductance, thereby reducing the ability 
of ions to pass through the ion pore. Such mutations lead to reduced current through the channels, 
and consequently cause a milder disease phenotype in comparison to the first three mutation 
classes (Sheppard et al., 1993; Veit et al., 2016). Class V mutations involve reduced expression of 
an otherwise functional protein (Marson et al., 2016), often involving splice site mutations 
(Highsmith et al., 1997; Marson et al., 2016) or promoter abnormalities (Veit et al., 2016). Lastly, 
Class VI mutations lead to proteins that are less stable (Marson et al., 2016) and are thus prone to 
accelerated rates of protein turnover (Silvis et al., 2003). Mutation classes I, II, and III lead to more 
severe disease phenotypes, while classes IV, V, and VI are typically milder (Marson et al., 2016). 
 
1.3 Airway Physiology and Cystic Fibrosis  
 
1.3.1 Basic Airway Physiology 
 
The primary function of the respiratory system is to facilitate gas exchange between the 
external environment and the circulatory system. In humans, there are approximately 300 million 
alveoli that accomplish gas exchange between the respiratory and circulatory systems, and these 
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alveoli receive inspired air from 23 bifurcations. This creates an extensive cumulative surface area 
that facilitates efficient gas exchange with pulmonary circulation (Widdicombe & Wine, 2015).  
 
Lining the airway are epithelial cells, the majority of which are ciliated (Bustamante-Marin 
& Ostrowski, 2017; Widdicombe & Wine, 2015), with roughly 200 cilia per cell (Rhodin, 1966). 
Separating the airway lumen and the epithelium is a thin film of surface liquid commonly known 
as airway surface liquid (ASL). This liquid barrier can be separated into two layers: the periciliary 
liquid (PCL) layer and a mucus gel layer lying directly on top of the PCL (Sturgess, 1977; 
Widdicombe & Wine, 2015; Yoneda, 1976). The PCL is a 7 µm thick fluid solution which contains 
a dense mesh of tethered mucins that project from the epithelial cilia and microvilli, and it plays 
an important role in excluding large particles from the cilia; in doing so, this enables the continuous 
beating of the cilia to propel mucus layer (Hattrup & Gendler, 2008; Sheehan et al., 2008).  
 
Inspired air often contains small particles and pathogens. While a minority of these inhaled 
particles and pathogens will be exhaled, most require other mechanisms for removal. In the upper 
airways, the accumulation of larger particles and pathogens over time may cause significant issues 
that interfere with normal respiratory function. The mucus layer lying on top of the PCL will bind 
to both particles and pathogens, at which point ciliary beating propels the mucus, a process called 
mucociliary clearance, out of the airway (Widdicombe & Wine, 2015). 
 
Airway surface liquid (ASL) is produced by the epithelial cells lining the lumen of the 
airway: the airway surface epithelia and submucosal glands (Widdicombe & Wine, 2015). In the 
larger airways, approximately 90% of the ASL is produced by the submucosal glands, and their 
distribution in the airways mimics deposition patterns of the largest inhaled particles (Widdicombe 
& Wine, 2015). As such, submucosal glands are most prevalent in the upper airways, which 
encounter the greatest rate of inhaled particle impacting the airway wall due to the turbulent nature 
of air flow in those anatomical regions. Below 2 mm diameter airways, the airflow becomes 
laminar, and the submucosal glands become more infrequent (Widdicombe & Wine, 2015). 
 
Optimal mucociliary clearance requires and appropriate airway hydration. The volume of 
ASL and mucus hydration are highly influenced by epithelial secretions (Widdicombe & Wine, 
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2015), and studies have been performed investigating the relationship between gland secretions 
and mucus clearance. Gland secretion is stimulatory of mucociliary clearance (Widdicombe & 
Wine, 2015), with one study showing that, following treatment of excised porcine tracheas with 
acetylcholine (ACh) to induce glandular liquid secretion, there was an approximate threefold 
increase in MCT (Ballard et al., 2002). Similarly, it was found that, in ferrets, there was an 
increased rate of mucus transport in response to mediators that promoted glandular secretions 
(Jeong et al., 2014). Lastly, it was found that stimulation of glandular secretions via cholinergic 
agonist methacholine in pigs caused greater clearance of tantalum microdisks in vivo (Fischer et 
al., 2019).  
 
In CF airways, it has been found that submucosal glands behave differently in comparison 
to normal glands. For example, CF glands respond abnormally to secretagogues (Joo et al., 2002; 
Nam et al., 2006; Salinas et al., 2005; Verkman et al., 2003; Wine & Joo, 2004), cytokines (Baniak 
et al., 2012), and inhaled pathogens (Luan et al., 2017), thus suggesting their involvement in CF 
pathogenesis (Ianowski et al., 2008; Salinas et al., 2005; Stoltz et al., 2015). Interestingly, the 
submucosal glands are innervated by the nervous system, which may promote liquid secretion 
(Ianowski et al., 2008; Wine, 2007). As a result of the vital role submucosal glands play in airway 
hydration, and their abnormal behaviour in CF airways, the ability to stimulate submucosal glands 
to rehydrate CF airways has enormous therapeutic potential.   
 
1.3.2 Neural Control of Airway Submucosal Glands.  
 
  It has been suggested that the airway submucosal glands are involved in two main functions 
(Wine, 2007). The first proposed function is a housekeeping innate mucosal defense against basal 
levels of inhaled particles, whereby low-level ASL secretions promote constitutive airway defense, 
in part through MCC, to keep the airways clear of pathogens and particles (Knowles & Boucher, 
2002; Wine, 2007). In this function, paracrine signals, released by epithelial and immune cells, as 
well as neural circuit intrinsic to the airway (i.e., networks of neurons within the airway), are 
responsible for ASL secretion in response to inhalation of small numbers of particles, as well as 
control of muscle tone and perfusion of the respiratory tract. These responses occur in the 
background, without the host being aware or perceiving its function. The housekeeping innate 
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immune response is highly effective, since most individuals rarely become sick or cough, despite 
inhalation of thousands of potentially noxious particles per day. In CF patients, this housekeeping 
function of the airway epithelia is compromised, increasing the probability of infection and 
inflammation (Wine, 2007).  
 
 The second proposed function is an emergency response to large and immediately life-
threatening insults, such inhalation of large particles, water, or irritating aerosols. This response is 
triggered by the central nervous system as a reflex to sensory activation in the airway and is 
mediated through the vagus nerve (Wine, 2007). The emergency response triggers reflexive glottal 
closure, airway constriction, pulmonary vessel dilation, cough, and copious glandular secretions 
(Wine, 2007). Glandular secretions via this reflex are primarily caused by cholinergic input, and 
it is characterized by large volumes of fluid and mucin secretion. This response is intact in CF 
(Wine, 2007), and is relevant to HTS treatment in CF patients. HTS activates this emergency 
response, causing high level secretion and, in some patients, triggers unwanted side effects of this 
emergency response, such as cough, airway constriction, and inflammation, reducing the 
tolerability of the treatment (Umeno et al., 1990; Wine, 2007).  
 
 Submucosal glands receive significant innervation from nerve terminals containing 
vasoactive intestinal peptide (VIP), ACh, substance P (SP), and nitric oxide synthase (NOS) 
(Wine, 2007). VIP, a strong secretagogue that acts through elevation of cAMP, causes considerable 
secretions from submucosal glands in non-CF subjects (Joo et al., 2002; Peatfield et al., 1983), an 
effect which is absent from CF airways (Joo et al., 2002). Furthermore, submucosal glands respond 
well to SP (Coles et al., 1984; Shimura et al., 1987). SP is released by sensory fibres and is another 
potent secretagogue, which induces glandular secretion, likely in a CFTR-dependent manner 
(Trout et al., 2001). Within the airway wall are sensory neurons, C-fibres and Aδ-fibres, which 
terminate within the surface epithelium (Hunter & Undem, 1999; Widdicombe, 2003). These 
sensory pathways activate sympathetic and parasympathetic centrally-mediated reflexes, as well 
as local anterograde release of SP and other neuropeptides (Ianowski et al., 2008; McDonald, 1987; 
Németh et al., 2003; Widdicombe, 2003). Local deposition of irritants or pathogens may trigger 
central reflexes if the insult is large enough, or activate these sensory pathways and promote local 
glandular secretions without involvement of the central nervous system (Ianowski et al., 2007). 
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Additionally, the ability of these sensory neurons to respond to hypertonic solutions (Fox et al., 
1995; Pedersen et al., 1998; Pisarri et al., 1992) makes the involvement of both the airway intrinsic 
neural circuitry and the central autonomic nervous system in HTS treatment extremely interesting.   
 
1.3.3 Airway Defense: Mucociliary Clearance and Cystic Fibrosis  
 
A key goal of cystic fibrosis research is understanding why a mutation in an anion channel 
(i.e., CFTR) results in the collapse of the innate immune system in the lung, with subsequent advent 
of chronic infection, inflammation, tissue remodeling and, ultimately, lung failure (Stoltz et al., 
2010). For several decades, the most significant hypothesis has been that CFTR is necessary to 
ensure mucociliary clearance of inhaled pathogens (Bustamante-Marin & Ostrowski, 2017; 
Hoegger et al., 2014; Sheehan et al., 2008), and thus CF patients suffer from abnormal bacteria 
clearance. However, the reasons why mucociliary clearance fails in CF is still a matter of debate.  
 
As mentioned above, the surface epithelium of the airways is covered in cilia, which 
interact directly with ASL. Recall that ASL contains a PCL layer, which is a low viscosity fluid 
layer that acts as a lubricant to facilitate ciliary beating, and resides underneath a mucus layer. The 
physical characteristics of ASL are crucial to proper MCC and airway health, and its abnormalities 
in CF explain the hallmark respiratory pathogenesis of the condition (Bustamante-Marin & 
Ostrowski, 2017). The composition of the mucus layer plays a substantial role in its capacity to be 
transported through the respiratory tract (Bustamante-Marin & Ostrowski, 2017).  Currently, there 
are two major hypotheses to explain the reduced mucociliary clearance observed in CF airways. 
 
For more than 20 years, the most prevalent hypothesis was that CF airways are dehydrated, 
and thus the PCL volume is reduced, inhibiting ciliary movement (Puchelle et al., 1995; Tarran et 
al., 2005). Airway surface liquid and PCL hydration depend on transepithelial secretion of fluid. 
Fluid production is largely driven by active anion transport into the lumen via CFTR and Ca2+-
activated Chloride Channels (CaCC), and fluid reabsorption is mediated by active Na+ absorption 
through a process involving Epithelial Na+ Channel (ENaC) (Tarran et al., 2005).  
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In CF airways, elevated sodium reabsorption due to hyperactive ENaC reduces volume of 
PCL, which leads to disruptions in MCC (Tarran, 2004; Tarran et al., 2005). For maintenance of 
effective MCC, the PCL must be maintained at an adequate height to separate the mucus layer 
from the cilia enough to allow effective ciliary beating and mucus propulsion through the airways 
(Puchelle et al., 1995; Tarran, 2004). The PCL is maintained at an ideal volume through a 
homeostatic process that regulates CFTR and ENaC activity. Part of that regulation is proposed to 
include the CFTR inhibition of ENaC activity. Thus, in CF airways, ENaC becomes hyperactive 
due to the lack of CFTR, and the PCL volume collapses, causing the cilia to become immobile. 
The end result is that mucociliary clearance fails, predisposing the CF lung to infection and lung 
failure (Joo et al., 2016; Nam et al., 2006; Zhou et al., 2011). 
 
This hypothesis has been  challenged by evidence that ENaC is not hyperactive in CF, and 
that PCL is normal in CFTR-/- swine (Chen et al., 2010). Other experiments have also shown that 
defects in submucosal gland activity may be most significant in initiating CF-related lung disease, 
including issues with pH (Gustafsson et al., 2012; Quinton, 2008), poor secretions, and mucus 
tethering (Hoegger et al., 2014).  
 
The second hypothesis proposes that MCC is reduced in CF due to failure of airway 
submucosal glands to release healthy mucin (Wine & Joo, 2004) in response to inhaled pathogens 
(Luan et al., 2014, 2017). The glandular secretion in CF airways is acidic, which reduces the 
antimicrobial properties of the ASL (Berkebile & McCray, 2014). Moreover, the mucus secreted 
by the glands in CF airway fail to detach from the gland opening, thus reducing mucociliary 
clearance (Hoegger et al., 2014). 
 
Regardless of the underlying reason for the failure of MCC, the mucus layer becomes 
relatively static. This facilitates the accumulation of pathogens, ultimately leading to frequent 
occurrences of respiratory infections (Puchelle et al., 1995); therefore, therapies often aim to 
improve airway hydration and rheological properties of the ASL layer. Enzymatic therapies, ion 
transport modulators, and treatments that break up mucus or enhance airway hydration are 
commonly prescribed therapies (Donaldson et al., 2006; Puchelle et al., 1995). 
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1.4 Inhaled Treatments to Facilitate Airway Clearance  
 
 Since airway dehydration appears to be at the core of CF lung pathology, great efforts have 
been directed at developing treatments to improve airway hydration. Several treatments are 
currently available to CF patients, including dornase alfa, dry powder mannitol inhalation, and 
hypertonic saline nebulization. 
 
Dornase alfa, a treatment that hydrolyzes the DNA present in sputum/mucus, seems to be 
effective in improving lung function and decreasing the frequency of pulmonary exacerbations, 
but with no apparent improvement in patient quality of life (Yang & Montgomery, 2018). 
Similarly, a Cochrane review was performed for inhaled dry powder mannitol, a treatment aimed 
at improving hydration by creating an osmotic gradient. Nolan et al. found that there was an 
apparent increase in lung function when compared with controls, but again, did not find any 
improvement in patient quality of life (Nolan et al., 2015). Lastly, I will discuss inhaled nebulized 
hypertonic saline, which will be the focus of this thesis.  
 
The evidence indicates that HTS causes an absolute increase in lung function when 
compared with isotonic controls, as well as a reduction in the frequency of pulmonary 
exacerbations (Elkins et al., 2006). Another study found that patients receiving nebulized 7% NaCl 
HTS solution had improvements in MCC and forced expiratory volume in one second (FEV1) 
(Donaldson et al., 2006), further supporting the role HTS may play in treatment of CF lung disease. 
Unlike the other treatments mentioned, HTS may also increase adult patient quality of life (Wark 
& Mcdonald, 2018). Although HTS is generally well-tolerated (Dellon et al., 2008; Rosenfeld et 
al., 2011; Wark & Mcdonald, 2018), it is important to recognize the limitations and unwanted side 
effects of this treatment. For some patients, the beneficial effects may be marginal and, due to the 
emergency reflex that HTS activates, some may experience coughing and airway constriction. For 
these reasons, some patients may struggle to tolerate HTS (Wine, 2007). Thus, there is a need for 
improved treatments with better health outcomes and reduced side effects.   
 
This dissertation will explore the role of the nervous system to HTS nebulization-triggered 
increase in MCC. The results may contribute to the development of new HTS formulations that 
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would modulate the contribution of the nervous system to the response to HTS to produce a more 
efficacious treatment, with longer duration and reduced negative side effects.  
 
1.5 Nebulized Hypertonic Saline 
 
 It is well understood that HTS improves MCC (Robinson et al., 1996; Tildy & Rogers, 
2015), though the mechanisms are not fully characterized. The predominant idea is that HTS 
functions to rehydrate the airways through osmotic forces, drawing fluid across the epithelium due 
to its hypertonicity, i.e., forcing water into the airway lumen by osmosis  (Goralski et al., 2018; 
Reeves et al., 2012). Additionally, the induction of coughing may play a role in clearing mucus 
(Dellon et al., 2008). However, recent studies from our laboratory have explored the relationship 
between HTS and the nervous system. It has been proposed that HTS, in addition to its osmotic 
effect, also stimulate sensory neurons in the airways, thus promoting active ion transport and fluid 
secretion by airway epithelia via the release of neuropeptides and thus improving airway hydration. 
The role of the nervous system was evidenced by an approximate 50% reduction in the effects of 
HTS on ASL height when combined with neural blockers (Luan et al., 2019). This suggests that it 
may be possible to target the nervous system to improve HTS treatment. However, it is currently 
unclear how the neurogenic response to HTS nebulization contributes to HTS-mediated 
improvements in MCC. This thesis seeks to answer this, by examining the role of the nervous 




Main Hypothesis: HTS-triggered increase in MCC is mediated by the nervous system. 
 
 The primary goal of my research was to investigate the role that the nervous system plays 
in HTS-mediated increase in MCC. I hypothesize that blocking airway neurons prior to nebulized 
HTS treatment will cause a reduction in MCC when compared with HTS in the absence of neural 
blockage. I expect that the reduction in liquid secretions when HTS is preceded by neural blockers 
(Luan et al., 2019) will translate to a reduction in MCC, due to the relationship described between 
fluid secretions and MCC in previous publications (Jeong et al., 2014; Puchelle et al., 1995).  
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Objective 1: Develop a MCC assay that is sensitive to changes in MCC in response to nebulized 
saline treatments. Existing ex vivo MCC assays (Hoegger et al., 2014; Joo et al., 2016) are limited 
for the purposes of detecting differences in MCC in response to HTS nebulization treatments. In 
those assays, the tissue is submerged in fluid, which effectively washes out the contribution of the 
treatment to airway hydration. Thus, a new ex vivo technique was required for investigating HTS 
and its effects on MCC. Once a method for incubating the tissue with neural blockers and/or CFTR 
channel inhibitors was developed, as well as methods for standardizing the initial state of the tissue 
preparations (i.e., lumen hydration and contamination with debris), it was possible to explore the 
role of the nervous system in MCC.  
 
Objective 2: Explore the effects of blocking the nervous system on HTS-mediated increases on 
MCC ex vivo in excised wild-type swine tracheas. The second portion of the thesis involved 
experiments on wild-type juvenile swine, whereby our assay was used to detect changes in MCC 
in response to various treatments. The overarching objective was to determine what effect, if any, 
blocking the nervous system has on HTS-mediated increases in MCC. My hypothesis was that the 
use of TTX prior to HTS nebulization would cause a significant reduction in MCC when compared 
with HTS alone. Additionally, I expected to see HTS combined with TTX to still be significantly 
better at promoting MCC than nebulization with isotonic saline (ITS), since the osmotic effect 
would remain.  
 
Objective 3: Explore the use of neural agonists capsaicin and menthol combined with HTS or ITS 
in improving MCC ex vivo in excised wild-type swine tracheas. To do so, menthol or capsaicin 
was combined with either ITS or HTS in wild-type juvenile swine experiments. The goal was to 
demonstrate whether agents that stimulate sensory neurons in the airways could be used to 
potentiate the effects of nebulized HTS or ITS. I hypothesized that the use of either menthol or 
capsaicin alongside HTS would cause a small increase in MCC when compared with HTS alone. 
When combined with ITS, I expected the use of menthol or capsaicin to cause a significant increase 
in MCC over ITS, but less MCC than HTS formulations due to the osmotic effect.  
 
Objective 4: Investigate the role of the nervous system in HTS treatment ex vivo  in CFTR-/- swine 
and CFTRinh-172 treated wild-type swine. Differences in airway physiology in CF, including that 
 12 
of the submucosal glands (Widdicombe & Wine, 2015), may affect the relationship between the 
nervous system and HTS-mediated MCC. Therefore, I performed experiments first using the 
CFTR inhibitor CFTRinh-172 to model the CF condition in wild-type juvenile swine, followed by 
experiments with transgenic CFTR-/- piglets. My hypothesis was that there would be a significant 
reduction in MCC when HTS was combined with TTX, when compared with HTS alone, in both 



























CHAPTER 2: MATERIALS AND METHODS  
 
Ethics Statement: This work was approved by the University of Saskatchewan’s Animal Research 
Ethics Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal 
use. 
 
2.1 Swine as a Model 
 
The porcine model is an excellent model for CF lung disease, as their respiratory anatomy 
and physiology more closely resemble that of humans than other animal models. Of significant 
importance is the similar distribution of submucosal glands between pigs and humans, and the 
availability of CFTR gene knockouts (Cutting, 2015; Keiser & Engelhardt, 2011). Swine CF 
models have demonstrated similar disease progression to that of patients, including lung 
pathogenesis. It has been shown that CFTR-/- pigs possess a reduced ability to protect against 
pathogens, as well as a higher incidence of lung infections, comparable to what is observed in 
humans (Stoltz et al., 2010). Moreover, CFTR-/- swine exhibit airway mucus buildup, bacterial 
infection, inflammation, and obstruction within the first few months of life (Ostedgaard et al., 
2011; Stoltz et al., 2010). Thus, the similarities in respiratory anatomy and physiology, and the 
availability of CFTR gene knockouts, make swine a highly practical model for the experiments 
performed for this dissertation. Additionally, there is a large body of published research on swine 
airway and lung disease that will allow us to better interpret our results, as well as compare and 
correlate findings with prior work performed in the Ianowski lab.  
 
2.1.1 Wild-type Swine 
 
 We used female and male wild-type swine purchased from the Prairie Swine Center 
(University of Saskatchewan, Canada) to perform all juvenile pig (~5-week-old juvenile pigs, 
~15kg) experiments, as well as control experiments for the CFTR-/- experiments. Juvenile pigs 
were used for all MCC experiments discussed in Chapter 3. Newborn and one-week-old wild-type 
piglets (~3kg) were used as controls for the CFTR-/- piglets in Chapter 4. The methods employed 
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will vary to some extent based upon the age of the animal, as described later. Euthanasia of wild-
type animals was performed using captive bolt. 
 
2.1.2 CFTR-/- Swine 
 
 We used gut-corrected CFTR-/- swine purchased from Exemplar Genetics (Iowa, USA). 
Exemplar Genetics provided a sow implanted with cloned embryos with the gut-corrected CFTR-
/- genotype (CFTR-/- ; TgFABP > pCFTR pigs). Gut correction indicates that the CF piglets, 
which would otherwise be born with meconium ileus (i.e., a form of bowel obstruction), have 
CFTR function restored to the intestines, preventing this complication from occurring (Stoltz et 
al., 2013). The sow was transported to Canada from the United States and was housed at the 
Western College of Veterinary Medicine Animal Care Unit, University of Saskatchewan, 
approximately four weeks prior to its due date for quarantine and to give the sow time to adjust to 
the novel environment in an effort to reduce stress prior to and during delivery. Delivery of the 
piglets was performed using caesarean section through a specialized veterinary surgeon team. 
Caesarean section was used to minimize exposure of the piglets to the stress of normal delivery 
and transit through the birth canal. The procedure took ~10 minutes from onset of anaesthesia, 
until euthanasia of the sow.  
 
Seven viable male piglets of normal weight were delivered, with one additional piglet that 
appeared to have died during gestation. A team of veterinary specialists and university researchers 
were on site to assist in getting the piglets to begin breathing; this included tactile stimulation to 
promote breathing, and removal of mucus in some subjects via suction tube. Each piglet was 
assigned a number and was monitored by a veterinarian or veterinarian technician for 24 h a day 
at the Western College of Veterinarian Medicine.  
 
The piglets were carefully monitored for food intake, bowel movement frequency and 
consistency, urination, temperature, weight, respiratory function, oxygen saturation, and general 
behaviour and responsiveness. If the veterinarian supervising observed or expected that a piglet’s 
health was declining, and would be expected to reach the End Humane Point in the proximate 
future, the animal was quickly destined for experimentation. Then, the animals were euthanized 
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via exsanguination under anesthesia, and the trachea was dissected out. Of the seven viable piglets, 
four had terminal complications during the first day. One survived to the second day, one survived 
five days, and one survived the full seven-day term of the experiment. It is for this reason that 
newborn and 1-week-old wild-type controls were necessary. 
 
2.2 Experimental Procedure 
 
2.2.1 Dissection of the Trachea  
 
Within 30 minutes of death, the pigs were transported to the Lab Animal Services Unit 
(LASU) at the Health Science Building, University of Saskatchewan. At this point, an incision was 
made along the ribcage, as well as along the thoracic region to allow access to the chest cavity. 
Once the trachea and lungs were located, it was separated from the esophageal tissue, and a cut 
was made across the most distal portion of the larynx, above the trachea, and at the carina below 
the trachea, excising the trachea from the animal. Immediately, the clamped trachea was placed in 
ice-cold Krebs-Ringer solution and oxygenated with 95% O2/95% CO2 gas.  
 
2.2.2 Tracheal Preparation and Cartilage Surgery in 5-Week-Old Swine. 
 
A section of ~1-1.5 inches was removed from the trachea and rinsed in phosphate buffer 
solution (PBS) to remove debris or blood that may have been present in the lumen; some pigs had 
more blood or other matter in the tracheal lumen than others, and this initial cleaning allowed for 
a more standardized starting point. After 10-15 seconds of rinsing in PBS, the tissue was pinned 
flat at each corner, with the luminal surface adjacent to the trachealis smooth muscle facing 
upward. This was followed by dissection of the cartilage rings (Fig. 2-1) to increase the access of 








Figure 2-1: Section of juvenile swine trachea following cartilage surgery. Cartilage was cut open  
to allow the pharmacological agents TTX and/or CFTRinh-172 to access the mucosa, including 





This was followed by dissection of the cartilage rings (see Fig. 2-1 above). A shallow 
incision was made across three or four cartilage rings in a longitudinal direction. Once a hole was 
made through the cartilage, a specialized round-tip elevator tool was used to create separation 
between the mucosa and the overlying cartilage. Using the elevator as a guide, the scalpel was 
used to cut through the remainder of the three to four cartilage rings. Forceps were then used to 
gently pull back the cartilage laterally along the entire length of the incision, while using the 
elevator to separate the cartilage from the mucosa and prevent tearing. Once a moderately sized 
(~0.5-0.75 inches in length, ~0.5 inches in width) window to the mucosa was established, the tissue 
was clamped off at both ends and placed within ice-cold Krebs-Ringer solution, alongside any 
required pharmacological agents for an incubation period of 15 minutes, as described below. At 
each point of this surgery, it was important to observe potential punctures or tears in the mucosa. 
In the event of a puncture, the tissue was discarded. This process took, on average, ~5 minutes. 
Krebs-Ringers solution was applied to the outside of the tissue periodically to prevent it from 
drying out; it was important that no fluid entered the lumen of the trachea during this process.  
 
2.2.3 Tracheal Preparation in 1-Week- and 1-Day-Old Swine 
 
The cartilage surroundings the trachea of young piglets is much less substantial than that 
of older animals, and thus it presents a much less severe barrier to the access of test drugs to the 
submucosa. Moreover, the size and fragile nature of the trachea necessitated forgoing the cartilage 
dissection. Therefore, young piglet tracheas went immediately to the incubation step described 
below. No other notable differences existed between juvenile and young swine experimental 
methods.  
 
2.2.4  Trachea Incubation in Test Solutions. 
 
Once the trachea preparation was ready, the next step was to incubate the tissue in Krebs-
Ringer solution containing one of four drugs combinations: no drug; CFTRinh-172 only; 
tetrodotoxin (TTX) only; CFTRinh-172 and TTX. CFTRinh-172 is a CFTR channel inhibitor (Caci 
et al., 2008) that is selective for CFTR, with no apparent effects on non-CFTR chloride channels 
(Ma et al., 2002). The mechanism of action is currently being explored but is not yet fully 
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understood (Kopeikin et al., 2010). For this project, CFTRinh-172 was used to simulate CF 
conditions in wild-type pigs. CFTRinh-172 purchased from Cedarlane Labs (Burlington, ON, CA) 
and dissolved in DMSO to achieve a concentration of 100mM. This was then dissolved in Krebs-
Ringer solution to achieve a final concentration of 100µM. The final concentration of DSMO was 
< 0.1%.  
 
Tetrodotoxin was purchased from Alomone labs (Jerusalem, Israel). TTX was used to 
cause blockage of tetrodotoxin-sensitive (TTXs) sodium channels (Scholz et al., 1998). A 1mM 
stock solution of TTX was dissolved in Krebs-Ringer solution to obtain a final working 
concentration of 1µM, which has been shown to block the TTXs sodium channels (Scholz et al., 
1998). It has been shown that TTX can reduce, but not eliminate, the synaptic activity of airway 
intrinsic neurons (Wine, 2007) without having an effect on epithelial ion secretion (Luan et al., 
2017). While other experiments have benefitted from the use of lidocaine to block TTX-insensitive 
Na+ channels (Luan et al., 2019; Scholz et al., 1998), lidocaine has been shown to decrease ciliary 
beat frequency (Ingels et al., 1994). This would be problematic, as changes in MCC could not be 
definitely attributed to the assigned nebulization treatment, due to potential changes in clearance 
resulting from abnormal ciliary behaviour. For the purpose of this experiment, complete blockage 
of neuronal activity was not necessary, as the goal of determining whether the nervous system was 




 To study the effect of HTS and other treatments on MCC, the lumen of the trachea 
preparation was connected to a nebulizer (MedPro, IN, USA) immediately following the 15-
minute incubation period. With the exception of the no treatment control group, all tissues received 
nebulization with either hypertonic (7% NaCl solution w/v) or isotonic (0.9% NaCl solution w/v) 
saline solutions, with some groups receiving menthol or capsaicin as well. Nebulization was 
performed for a 90-second period, delivering approximately 0.3 ml of liquid, much of which was 
allowed to freely flow out of the preparation through the open end of the trachea opposite to the 
nebulized end to best-simulate patient use of the treatment, whereby a patient inhales the nebulized 
product and then exhales the excess aerosols.  
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Six nebulized saline formulations were used for the experiments: HTS only; ITS only; HTS 
+ Menthol; ITS + Menthol; HTS + Capsaicin; and ITS + Capsaicin. Experiments involving 
capsaicin were performed in a ventilated hood for safety. A 1M stock solution of menthol was 
added to either HTS or ITS to achieve a final concentration of 1mM (Oz et al., 2017). A 100mM 
stock solution of capsaicin was added to HTS or ITS to achieve a final concentration of 10µM 
(Matera et al., 1997).  
 
2.2.6 Mucociliary Clearance Assay 
 
After nebulizing the trachea, scissors were used to cut the trachea longitudinally to open 
the trachea. In 5-week-old pigs, scissors were used to cut lengthwise at two locations, with 
approximately one third of the trachea discarded; this was to allow the trachea to be opened and 
laid flat in the imaging chamber. An effort was made to standardize cuts between different 
experiments. For the 1-day-old and 1-week-old piglets, the smaller circumference of the trachea 
allowed for a single lengthwise incision, therefore opening the trachea without discarding any of 
the tissue.  
 
The tissue was then placed in an agarose plate with a layer of gauze lining the bottom. A 
small volume of Krebs-Ringer solution was used to soak the gauze; it was important to ensure the 
volume of solution used was small enough to avoid flooding the surface of the trachea during 
imaging. The purpose of this was to maintain humidity and tissue health during the experiment, 
prolonging the period during which the tissue could be imaged. The tissue was then pinned to the 
plate to provide support and maintain a relatively flat surface. 
 
Then, tantalum disks (250 µm diameter and 25 µm thickness) were placed along the 
luminal surface, at the caudal end of the preparation, to allow adequate space for movement toward 
the proximal portion. For 5-week-old pigs, a minimum of eight particles were placed, with a 
maximum of twelve. The number placed would vary based upon the time taken to place them. The 
goal was to minimize time spent, while maximizing coverage of the luminal surface. For the 
smaller diameter 1-day-old and 1-week-old piglets, a minimum of six particles were used. An 
effort was made to place the particles in a conserved manner, with a standard two rows of four 
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particles. Areas of the tissue damaged from clamping were avoided during particle placement. 
Lastly, particles were not to be placed on the trachealis smooth muscle, due to poor observed 
movement in preliminary experiments. The process of opening the trachea and placing particles 
typically took ~2-3 minutes, during which the tissue was exposed to the surrounding environment. 
 
2.2.7 Tracking Mucociliary Clearance 
 
Once the tantalum particles were placed, the trachea was placed in the DH-35iL 
temperature control system (Harvard Apparatus, Saint-Laurent  QC, Fig. 2-2). This chamber was 
temperature-regulated, allowing for a physiological temperature of 37 °C to be maintained (Fig. 
2-2B). The chamber received humidified 95%O2/5%CO2 gas mixture to replicate physiological 
conditions. The position of the tantalum disks was recorded with a digital camera (MiniVid, GA, 
USA, Fig. 2-2A and Fig. 2-3) every 30 seconds for as long as the disks were mobile, with a 








Figure: 2-2A shows simplified pictorial representation of imaging set-up excluding the DH-35iL 
chamber, modified from Joo et al (Joo et al., 2001).  2-2B is a fully assembled DH-35iL chamber 
















Figure 2-3. Subsequent images were used to analyze particle movement. This figure is  
composed of two consecutive images merged. The change in X-position and Y-position  
between consecutive images was measured, then used to calculate the hypotenuse of  




Figure 2-4. Particle movement traced over a 20-minute interval in ex vivo swine trachea 
preparation following 90-seconds of HTS nebulization. This figure consists of the first and last 
images merged. Particles placed on the most distal (left) end of the trachea in an approximate 4x4 












2.3 Analysis of Mucociliary Clearance Rate 
 
The efficacy of mucociliary clearance could be understood as how many particles are 
cleared and how fast the airway ciliary escalator is capable of removing them. Thus, a treatment 
for improving MCC would, ideally, increase both the number of particles cleared and the how fast 
they are removed. However, determining if a treatment improved clearance using our ex vivo 
preparation was more complicated than it initially seemed. For example, a preparation where a 
single tantalum disk moves 10 times faster after treatment would indicate that the treatment was 
very effective if one measures maximum MCC rate. However, if none of the other particles move 
at all, that would be a misguided conclusion according to our initial definition, which included the 
number of cleared particles to determine MCC efficacy.  Similar problems arise when using other 
variables such as number of immobile or mobile particles, delay to start moving, average 
maximum particle speed, etc. (please see Appendix 1 for a detailed description of the development 
of the MCC assay and measurements). Thus, we decided to measure several variables that, 
together, provide evidence of MCC efficacy under different conditions.  
 
2.3.1 Number of Particles that Travel 5 mm 
 
The most informative parameter was the average number of particles that travelled a 
minimum of 5 mm. The distance of 5 mm was established because it was large enough to detect 
differences between treatment groups. Other distances were tested, including 1 mm, 1.5 mm, 2 
mm, and 4 mm, but were less sensitive to differences between groups. Distances larger than 5 mm 
become gradually more problematic, as changes in particle movement cannot be definitely 
attributed to MCC; for example, the presence of tissue damage near the end of the tissue, or 
accumulation of mucus at the end of a preparation, could both artificially reduce movement. This 







2.3.2 Average Maximum Particle Speed 
 
Average maximum speed was also measured using the overall distance travelled in a 30-
second interval, i.e., the time between two consecutive images. Taking the time-point in which the 
particle travelled the greatest distance allowed for maximum speed to be calculated, which could 
be then averaged between all particles and experiments. It should be noted that, in order to be 
included in calculations of speed, the particle was required to have travelled a minimum of 1 mm. 
This requirement was to prevent results from being skewed in treatment groups that have a higher 
proportion of particles that are immobile or minimally mobile. Further, this allows for the 
comparison of movement behaviour of particles between treatment groups when particles/mucus 
are reasonably mobile.  
 
2.3.3 Number of Minimally Mobile Particles  
 
The last parameter of interest was the number of particles that were minimally mobile, 
which was defined as travelling less than 1 mm. This measure helps to demonstrate a treatment’s 
ability to induce movement. While the number of particles that travel 5mm shows how well a 
treatment can propagate movement over longer distances, this measure tells us how well a 
treatment can initiate movement. The two measures are complementary, but the induction of 
movement does not necessarily imply high levels of movement, as will be shown later on.   
 
2.3.4 Maximum Distance Travelled in 20 Minutes in CFTR-/- Piglets 
 
Measures of clearance in the CFTR-/- piglets varied slightly, likely due to the substantial 
differences in piglet health. With the CFTR-/- piglets, each trachea was divided into two for two 
experiments: HTS and HTS + TTX. Significant heterogeneity in the health of CF piglets 
necessitated normalizing each piglet to itself, and then performing paired t-tests. While speed 
calculations and the number of minimally mobile particles in the CFTR-/- piglets remained 
unchanged, the number of particles observed to travel 5 mm had to be modified to accommodate 
interindividual differences observed. Instead of determining how many particles travelled 5 mm, 
we decided to determine how far particles travelled as a percentage of the maximum distance in 
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that animal. We measured the maximum distance any particle travelled for a given piglet in 20 
minutes, and then calculated percentage values for each other particle. For example, if the most 
mobile particle in a pig (i.e., examining all particles from both experiments performed in a single 
piglet) travelled 1 mm, then another particle from the same piglet that travelled 0.6 mm would be 
assigned a value of 60%. In doing so, it helped to control for the differences that existed between 
animals related to the health of the animal, and allowed for more effective comparisons between 
treatment groups. With the standard value of 5 mm, it was often the case that zero particles crossed 
that distance threshold in an animal, regardless of treatment type. In essence, we are still comparing 
the relative ability of the treatment groups to promote high levels of MCC, whereby a higher 
average percentage means that there was greater MCC, normalized to the pig’s health. Normalizing 
each piglet to itself was not ideal, but it was a necessary decision to avoid massive variance due to 
small sample size and high heterogeneity in the piglets. This was not an issue for the wild-type 
control animals, and we did not consistently measure the same two treatment groups in each 
animal, so we opted to remain consistent with previously described wild-type animal analyses. 
Overall, both analyses measure the same thing, but are presented in slightly different ways.  
 
2.4 Statistical Analyses  
 
 A variety of statistical analyses were performed. For wild-type juvenile swine experiments 
(Chapter 3), comparisons of particles travelling 5 mm, minimally mobile particles, and mean 
maximum particle speed were analyzed using one-way ANOVAs with Tukey’s HSD post-hoc 
multiple comparisons. Additionally, Bartlett’s test for homogeneity of variances was used and, in 
the event of violation of this assumption, Brown-Forsythe correction for unequal variances was 
applied. For the percentage of particles cleared over time, a mixed methods two-way ANOVA 
using Greenhouse-Geiser epsilon correction factor when Mauchly’s sphericity test failed. Tukey’s 
HSD post-hoc multiple comparisons were used to determine where significant differences 
occurred.  
 
 In CFTR-/- swine, paired t-tests were used. Each piglet had its trachea divided into two 
sections: one would receive HTS alone, and one would receive HTS following preincubation with 
TTX. This allowed each piglet act as its own control. 1-week- and 1-day-old wild-type control 
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piglets used unpaired t-tests, alongside F-tests for ensuring equal variances. If unequal variances 
were detected, Welch’s correction was applied. The rationale behind using a different method of 
comparison was that, unlike in CFTR-/- swine, there was not high levels of heterogeneity between 
experiments, and thus normalizing each wild-type swine to itself was unnecessary. Additionally, 
incomplete experimental groups were used in these controls, and so each piglet did not necessarily 
receive the same two treatments of HTS and HTS + TTX. Rather than removing a number of 
experiments and only using the pigs that received these two treatment groups, it was decided to 
perform an unpaired t-test. For the purpose of determining differences between HTS and HTS + 
TTX in these wild-type controls, this method was sufficient.  
 
2.5 Inclusion/Exclusion Criteria  
 
Not all experiments were included in the data analysis for this thesis. The most basic, 
common reason for exclusion was puncturing of the mucosal layer during cartilage dissection. This 
would cause fluid to enter the tracheal lumen, where it could potentially influence particle 
movement later on. Experiments with less than three mobile particles were excluded, as it was a 
sign of unobservable epithelial damage. Preliminary experiments found that preparations with 
surface damage displaced substantially less particle movement. Additionally, areas of the tissue 
affected by clamping displayed little to no movement, further supporting this hypothesis. Damage 
to the luminal surface was difficult to observe directly, so these criteria were created to avoid 
attributing minimal movement to the treatment group in cases where the tissue’s health may have 
been a confound. For this reason, it was decided that a reasonably healthy tissue would display 
movement of three or more particles. For the purpose of exclusion, an immobile particle was 
defined as any particle that completely lacked mobility, excluding any movement that could clearly 








CHAPTER 3: HYPERTONIC SALINE NEBULIZATION TRIGGERS AN INCREASE 
IN MUCOCILIARY CLEARANCE MEDIATED BY THE NERVOUS SYSTEM 
  
Inhaled nebulized hypertonic saline is a commonly used treatment in CF patients to restore 
hydration and improve lung clearance (Robinson et al., 1996). Currently, the exact mechanisms of 
HTS treatment effects on the airway are not completely understood (Tildy & Rogers, 2015). 
Gaining a better understanding of how HTS improves MCC (Robinson et al., 1996) could be 
hugely beneficial in creating new therapies or improving existing ones by extending their duration 
or enhancing the intensity.  
 
It is well-understood that HTS functions, in some part, through the production of an 
osmotic gradient that draws fluid into the airway to increase the ASL height (Goralski et al., 2018), 
and thus MCC (Elkins et al., 2006; Tildy & Rogers, 2015). However, it has been shown that HTS 
stimulates airway sensory neurons to trigger ASL secretion by airway submucosal glands. It has 
been shown that there is an approximate 50% reduction in the effects of HTS treatment on ASL 
height in vivo when pigs are treated with neural blockers atropine and lidocaine (Luan et al., 2019). 
The same observation was made in ex vivo swine trachea preparations using neural blockers, 
including TTX (Luan et al., 2019).  Thus, it was proposed that HTS triggers a neural response, 
whereby the nervous system is recruited to facilitate the production and secretion of fluid into the 
airways and improve hydration (Luan et al., 2019).  
 
We hypothesized that the HTS-triggered increase in mucociliary clearance is also 
dependent on the stimulation of the nervous system. Our results show that inhibition of neuronal 
function does, indeed, reduce the HTS-triggered mucociliary clearance. Moreover, stimulation of 
airway sensory nerves with capsaicin or menthol stimulates clearance. Menthol acts primarily 
through TRPM8 receptors in the airways to initiate autonomic responses, such as mucosal 
secretions, which are mediated by C-fibres and Aδ-fibres (McKemy, 2007; Plevkova et al., 2012; 
Xing et al., 2008). Capsaicin acts primarily through TRPV1 receptors, which are predominant in 






3.1.1 Assay Validation 
 
The initial goal of the project was to validate the mucociliary clearance assay by confirming 
that it can detect changes in MCC between treatment groups. It is well-established that HTS causes 
a significant increase in lung function through improved MCC (Elkins et al., 2006; Robinson et 
al., 1996). To validate the methods, it was necessary to first replicate these findings, using our 
assay to show a significant increase in MCC in tracheas that received nebulized HTS treatment. 
The HTS treatment group showed 5.3 ± 0.6 (mean ± SEM) particles that cleared 5 mm, which was 
significantly larger than the control groups. The ITS treatment group, which acted as a nebulization 
control for HTS, had only 1.9 ± 0.7 particles crossing the 5mm distance threshold. Lastly, the No 
Treatment control group showed 2.0 ± 1.4 particles crossing 5mm (Fig. 3-1; n = 15 for HTS, n = 
13 for ITS, n = 6 for No Treatment; p < 0.05, one-way ANOVA with Tukey’s HSD post-hoc 
testing). These findings support the use of this assay for comparing MCC of different treatment 
groups. It was expected that HTS should cause an increase in MCC over tissues treated with ITS 
and those that lacked nebulization treatment, and therefore we can conclude that these data are 





Figure 3-1. Mucociliary clearance in excised wild-type 5-week-old swine trachea following 
treatment with hypertonic saline, isotonic saline, or no treatment (HTS, n = 15 trachea sections 
from 15 swine; ITS, n = 13 trachea sections from 13 swine; No treatment, n = 6 from 5 swine). A) 
Average number of particles that travelled a minimum of 5 mm in the 20-minute imaging interval. 













































































whereby q (31) = 4.710, p = 0.0062. HTS also caused a significant increase over No Treatment, 
whereby q (31) = 3.586, p = 0.0424. B) Average number of minimally mobile particles between 
the groups. HTS led to significantly fewer minimally mobile particles when compared with ITS, 
whereby q (31) = 5.544, p = 0.0013. No statistically significant difference was observed between 
HTS and No Treatment. C) Mean maximum particle speed. HTS was shown to have a significantly 
higher mean maximum particle speed when compared with ITS, p = 0.0183. HTS was also shown 
to have a significantly higher mean maximum particle speed when compared with No Treatment, 
whereby p = 0.0179. Data are presented as mean ± SEM. Means for A and B were analyzed with 
ordinary one-way ANOVA and Tukey’s HSD multiple comparisons. Brown-Forysthe correction 
for unequal variances was applied to C with Dunnett’s T3 multiple comparisons testing. 
Significance level was set at p = 0.05.  
 
Similarly, preparations treated with HTS displayed 1.3 ± 0.4 particles travelling less than 
1 mm (i.e., minimally mobile) compared to ITS-treated preparations, which showed 4.1 ± 0.6 
particles minimally mobile (Fig. 3-1B, p < 0.05, one-way ANOVA with Tukey’s HSD post-hoc 
testing). No other significant differences were observed, but the small n-value of the No Treatment 
group possibly accounts for the lack of statistically significant difference between HTS and No 
Treatment groups; further repetitions are necessary to better characterize this relationship. Lastly, 
examining Figure 3-1C for mean maximum particle speed, it is apparent that HTS causes a 
significant increase in mean maximum particle speed when compared with ITS and No Treatment  
(Fig. 3-1C, p < 0.05, one-way ANOVA with Brown-Forsythe Correction and Dunnett’s T3 
multiple comparisons). HTS showed a mean maximum particle speed of 2.9 ± 0.5   mm/min, while 
ITS and No Treatment showed 1.3 ± 0.2 mm/min and 1.1 ± 0.3  mm/min, respectively.  
 
  The results demonstrate that our mucociliary clearance assay is capable of measuring 
HTS-triggered increase in clearance and, thus, can be used to study other treatments, including 






3.1.2 Blocking Neuronal Function Inhibits the Effect of HTS Nebulization on MCC  
 
Treatment with nebulized HTS triggers neurogenic ASL secretion (Luan et al., 2019). This 
effect can be blocked by treatment with the sodium channel blocker tetrodotoxin (TTX), which 
functions by inhibiting action potentials in some neurons (Scholz et al., 1998). Thus, we tested the 
effect of TTX on HTS-triggered mucociliary clearance. 
 
  While HTS treatment triggered 5.3 ± 0.6 particles to travel 5 mm, preincubation with TTX 
significantly reduced the number of cleared particles to 1.6 ± 0.6, similar to the results of ITS 
treatment (Fig. 3.2A; n = 15 for HTS, n = 17 for HTS + TTX, n = 13 for ITS; p < 0.05, one-way 
ANOVA and Tukey’s HSD post-hoc multiple comparisons). Consistent with this result is the 
finding that HTS also had significantly fewer particles that were minimally mobile when compared 
with HTS + TTX (Fig. 3.2B; p < 0.05, one-way ANOVA with Tukey’s HSD post-hoc multiple 
comparisons). HTS alone saw 1.3 ± 0.4 minimally mobile particles, whereas preincubation with 
TTX prior to HTS nebulization raised that value to 4.5 ± 0.7. The number of minimally mobile 
particles in the ITS group was similar to that of HTS + TTX. Lastly, no statistically significant 
differences in mean maximum particle speed were observed in tissues treated with TTX, 
suggesting that the speed of mobile particles is similar, but less particles are mobile overall when 
TTX is applied.  
 
These findings provide evidence that the neurogenic effect of HTS treatment contributes 
to the stimulation of MCC by increasing the number of cleared particles, but has no effect on the 







Figure 3-2. Mucociliary clearance in excised wild-type 5-week-old swine trachea following 
treatment with hypertonic saline, isotonic saline, or a combination of HTS and TTX (HTS, n = 15 
trachea sections from 15 swine; ITS, n = 13 trachea sections from 13 swine; HTS + TTX, n = 17 
from 17 swine). A) Average number of particles that travelled a minimum of 5 mm. HTS caused a 
significant increase in the mean particles travelled 5 mm versus the HTS + TTX treatment group, 
whereby q (42) = 5.738, p = 0.0006. HTS was shown to cause an increase over ITS as well, 
whereby q (42) = 4.970, p = 0.003. B) Number of minimally mobile particles. HTS caused a 
significant reduction compared to ITS. HTS also caused a significant reduction in minimally 































































mobile particles when compared with HTS + TTX, whereby q (42) = 5.870, p = 0.0005. C) Mean 
maximum particle speed, and found HTS to be significantly greater than ITS, as described earlier. 
No significant difference in maximum particle speed was observed between HTS + TTX and ITS 
or HTS. Data are presented as mean ± SEM. Means for A and B were analyzed with ordinary one-
way ANOVA and Tukey’s HSD multiple comparisons. Brown-Forysthe correction for unequal 
variances was applied to the ANOVA for C, with Dunnett’s T3 multiple comparisons testing. 
Significance level was set at p = 0.05.  
  
3.1.3 Sensory Agonists Increase Mucociliary Clearance 
 
To further test the potential role of the nervous system in improving mucociliary clearance, 
we tested the effect of adding the sensory agonists capsaicin and menthol. Capsaicin has been 
shown to increase HTS-triggered airway ASL production (Luan et a., 2019). Addition of capsaicin 
to ITS treatment increased the number of particles cleared from 1.9 ± 0.7 in ITS to 5.6 ± 1.4 for 
ITS + Capsaicin-treated preparations (Fig. 3-3A; n = 15 for HTS, n = 13 for ITS, n = 5 for ITS + 
Capsaicin, n = 7 for HTS + Capsaicin; p < 0.05; one-way ANOVA and Tukey’s HSD post-hoc 
multiple comparisons). Interestingly, capsaicin had no significant effect on HTS-treated 
preparations, where the number of particles cleared was 5.3 ± 0.9 for HTS + Capsaicin, and 5.6 ± 




Figure 3-3. Mucociliary clearance in excised wild-type 5-week-old swine trachea following 
treatment with HTS, ITS, a combination of HTS and capsaicin, or a combination of ITS and 
capsaicin (HTS, n = 15 trachea sections from 15 swine; ITS, n = 13 trachea sections from 13 
swine; HTS + Capsaicin, n = 7 from 7 swine; ITS + Capsaicin, n = 5 from 5 swine). A) Average 
number of particles that travelled a minimum of 5 mm. HTS was shown to cause a significant 





































































































































caused a significant increase over ITS, whereby q (36) = 4.393, p = 0.0185. ITS + Capsaicin 
caused a significant increase over ITS as well, whereby q (36) = 3.881, p = 0.0445. No statistically 
significant differences were observed between HTS, HTS + Capsaicin, or ITS + Capsaicin 
treatment groups. B) Percentage of particles that have travelled 5 mm as a function of time. ‘a’ 
denotes a statistically significant difference from HTS for a given time point. ‘b’ denotes a 
statistically significant difference from HTS + Capsaicin for a given time point. Only HTS was 
greater than ITS at minute 5, while both HTS + Capsaicin and HTS were statistically significantly 
greater than ITS at minute 15 and 20, p < 0.05. C) Average number of minimally mobile particles. 
HTS was shown to have significantly less than ITS. HTS + Capsaicin also showed a significant 
reduction in minimally mobile particles when compared with ITS, whereby q (36) = 5.575, p = 
0.0019. No additional significant differences were observed. D) Mean maximum particle speed. 
No statistically significant differences were observed. Data are presented as mean ± SEM. Means 
in A, C, and D were analyzed with ordinary one-way ANOVA and Tukey’s HSD multiple 
comparisons post-hoc testing. Means in B were compared using mixed methods two-way ANOVA 
with Greenhouse-Geiser correction factor where necessary, and Tukey’s HSD post-hoc testing. 
Significance level was set at p = 0.05.  
 
 Similarly, HTS + Capsaicin showed 0.8 ± 0.3 minimally mobile particles, which was 
significantly less than the 4.1 ± 0.6 minimally mobile particles observed in ITS (Fig. 3-3A; p < 
0.05, one-way ANOVA and Tukey’s HSD post-hoc multiple comparisons). ITS + Capsaicin, 
which had 1.8 ± 1.1 minimally mobile particles, was not significantly different from ITS (Fig. 3-
3C; p > 0.05, one-way ANOVA and Tukey’s HSD multiple comparisons). The small sample size 
of ITS + Capsaicin will necessitate additional experiments. Lastly, no significant differences in 
mean maximum particle speed were observed when tissues were treated with capsaicin (Fig. 3-
3D; p > 0.05, one-way ANOVA).  
 
 Despite there being no difference between HTS and HTS + Capsaicin in the measurements 
described above, it was still possible that there may be a difference with respect to the time course 
of the response to these treatments. Thus, in order to study the time course of the effect of the 
treatment we analyzed the cumulative percentage of particles that have travelled a distance of 5 
mm as a function of time (Fig. 3-3B). At minute 10, minute 15, and minute 20, a statistically 
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significant difference can be observed between HTS and ITS (Fig 3-3B, p < 0.05, mixed methods 
two-way ANOVA with Greenhouse-Geiser correction and Tukey’s HSD post-hoc testing). At 
minute 15 and minute 20, HTS + Capsaicin showed greater clearance compared to ITS (Fig 3-3B, 
p < 0.05, mixed methods two-way ANOVA with Greenhouse-Geiser correction and Tukey’s HSD 
post-hoc testing). Despite there being an absolute difference in clearance between ITS + Capsaicin 
and ITS alone (Fig. 3-3A), no significant difference was observed in this analysis. It can be 
observed that ITS + Capsaicin is highly similar to both HTS and HTS + Capsaicin groups, and 











Figure 3-4. Mucociliary clearance in wild-type 5-week-old excised swine trachea following 
treatment with HTS, ITS, a combination of HTS and menthol, or a combination of ITS and menthol 
(HTS, n = 15 trachea sections from 15 swine; ITS, n = 13 trachea sections from 13 swine; HTS + 
Menthol, n = 7 from 7 swine; ITS + Menthol, n =10 from 10 swine). A) Average number of particles 
that travelled a minimum of 5 mm in the 20-minute imaging interval. HTS was shown to cause a 




































































































































q (41) = 5.154, p = 0.004. ITS + Menthol caused a significant increase over ITS, whereby q (41) 
= 5.890, p = 0.0009. HTS + Menthol did not cause a statistically significant difference over the 
ITS treatment group. B) Percentage of particles that have travelled 5 mm as a function of time. ‘a’ 
denotes a statistically significant difference from HTS for a given time point. ‘b’ denotes a 
statistically significant difference from ITS + Menthol for a given time point. ITS + Menthol and 
HTS were statistically significantly greater than ITS at minute 10, 15, and 20, p < 0.05. No other 
significant differences were observed. C) Number of minimally mobile particles. HTS + Menthol 
showed significantly less minimally mobile particles compared with ITS, whereby q (41) = 5.798, 
p = 0.0011. ITS + Menthol showed a significant reduction compared with ITS, whereby q (41) = 
6.581, p = 0.0002. No significant differences were observed between HTS, HTS + Menthol, and 
ITS + Menthol. D) compares mean maximum particle speed. HTS shows significantly greater 
maximum particle speed than ITS. No additional significant differences were observed. Data are 
presented as mean ± SEM. Means in A, C, and D were analyzed with ordinary one-way ANOVA 
and Tukey’s HSD multiple comparisons post-hoc testing. Means in B were compared using mixed 
methods two-way ANOVA with Greenhouse-Geiser correction factor where necessary, and 
Tukey’s HSD post-hoc testing. Significance level was set at p = 0.05.  
 
 Menthol was the second sensory agonist used to test the involvement of the nervous 
system in MCC (Fig. 3-4). Menthol has been shown to stimulate airway secretions (Chiyotani et 
al., 1994), and appears to have a positive effect on mucus clearance in non-CF obstructive lung 
disease (Hasani et al., 2003), making it a solid candidate for testing. ITS + Menthol caused 6.2 ± 
0.7 particles to travel 5 mm, which was significantly more than the 1.9 ± 0.7 particles in ITS 
(Fig. 3-4A; n = 15 for HTS, n = 13 for ITS, n = 10 for ITS + Menthol, n = 7 for HTS + Menthol; 
p < 0.05, one-way ANOVA with Tukey’s HSD multiple comparisons). No significant 
differences were observed between HTS, HTS + Menthol, or ITS + Menthol groups, and they 
appear approximately equivalent in their number of particles that travel 5 mm. HTS + Menthol 
was not significantly greater than ITS (Fig. 3-4A; p > 0.05, one-way ANOVA with Tukey’s 
HSD multiple comparisons). That said, the HTS + Menthol group had the smallest n-value in this 
comparison and the sample size should be increased. 
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 When comparing the cumulative percentage of particles that have travelled a distance of 5 
mm as a function of time, no statistically significant difference was observed at 5 minutes (Fig. 3-
4B, p > 0.05, mixed methods two-way ANOVA with Greenhouse-Geiser correction). At 10, 15, 
and 20 minutes, ITS + Menthol and HTS both showed statistically higher percentages than ITS 
(Fig. 3-4B, p < 0.05, mixed methods two-way ANOVA with Greenhouse-Geiser correction and 
Tukey’s HSD multiple comparisons). Similar to 3-4A, no significant difference was observed 
between HTS + Menthol and ITS. HTS + Menthol appears to be approximately equivalent to the 
HTS treatment group, and so additional experiments may help to clarify this relationship.  
 
Comparing the average number of minimally mobile particles (Fig. 3-4C), a few significant 
differences were observed. As described earlier, HTS had significantly less minimally mobile 
particles when compared with ITS (Fig. 3-4C; p < 0.05, one-way ANOVA with Tukey’s HSD 
multiple comparisons). ITS + Menthol showed 0.91 ± 0.5 minimally mobile particles, a significant 
reduction when compared to ITS (Fig. 3-4C; p < 0.05, one-way ANOVA with Tukey’s HSD 
multiple comparisons). Interestingly, despite not causing a significant increase in particles 
travelling 5 mm (Fig. 3-4A), HTS + Menthol, which had 1.0 ± 0.4 minimally mobile particles, did 
cause a significant reduction in minimally mobile particles when compared with ITS (Fig. 3-4C; 
p < 0.05, one-way ANOVA with Tukey’s HSD multiple comparisons). No statistically significant 
differences were observed between HTS, HTS + Menthol, and ITS + Menthol. Mean maximum 
particle speed was not shown to be different between either HTS + Menthol or ITS + Menthol 
when compared with ITS or HTS (Fig. 3-4D; p > 0.05, one-way ANOVA). These findings 
highlight menthol as a strong potentiator of MCC, as evidenced by the ability of ITS + Menthol to 




 The key finding in our research is that HTS-mediated increases in MCC involve the 
nervous system. HTS nebulization caused a significant increase in both particles that travel large 
(5 mm) distances and a significant reduction in minimally mobile particles (Fig. 3-1) when 
compared with an ITS-treated preparation. The effect of HTS nebulization on MCC were 
remarkably similar to those reported on the effect of the treatment on the changes in airway surface 
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liquid layer height reported in previous studies from our lab (Luan et al., 2019). First, No Treatment 
and ITS treatment groups were approximately equal in the change in ASL at all time-points, 
including the end time-point of 18 minutes. Similarly, we see close values for the number of 
particles travelled 5 mm (Fig. 3-1A). When comparing the change in ASL between treatment 
groups at the end-time (18 minutes), the study showed that HTS-treated tracheas had close to 
double the change in ASL height compared to ITS and No Treatment. Comparatively, the MCC 
experiments described above show that no treatment and ITS treatment had between one-third and 
one-half of the clearance seen in HTS-treated preparations (Fig. 3-1A). With respect to minimally 
mobile particles (Fig. 3-1B), we can also see that there are fewer particles remaining stationary or 
minimally mobile in the HTS-treated tissues. Finally, we saw that there was an increase in the 
mean maximum particle speed in HTS tissues, when compared with ITS or No Treatment. Overall, 
we can conclude that, when compared with ITS or No Treatment, HTS experiments demonstrate 
more mobile particles, a greater number of particles travelling long distances, and higher velocities 
of clearance. These experiments allowed us to achieve our first objective, whereby we sought to 
confirm that our assay was sensitive to changes in MCC that occur in response to treatments. From 
here, the next step was determining what role, if any, the nervous system plays in HTS-triggered 
MCC.  
 
The experiments comparing the use of HTS + TTX to HTS alone address the main question 
of this thesis: is the HTS-mediated increase in MCC dependent on the nervous system? After 
finding that HTS-mediated increases in ASL height are reduced by roughly 50% in the presence 
of neural blockers (Luan et al., 2019), the next logical step was to determine whether this translated 
to any effect in the more clinically relevant parameter of MCC. It was expected that there would 
be a reduction in MCC in response to HTS when the tissue was incubated using TTX, a voltage-
gated Na+ channel blocker (Scholz et al., 1998). Initially, it was expected that HTS + TTX would 
have less clearance when compared with HTS alone, but still exhibit greater clearance than ITS. 
This is because of in vivo and ex vivo ASL height experiments, where HTS combined with neural 
blockers showed a 50% reduction in HTS-mediated increases in ASL height, indicating that some 
level of HTS response was still present with neural blockers since the osmotic effect of HTS would 
not be affected by neural blockers (Luan et al., 2019). Figure 3-2A showed that TTX significantly 
blocked HTS-induced increase in MCC, as there was no significant difference between HTS + 
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TTX and ITS. It is apparent that this degree of neural block eliminated the effects of HTS on 
particle clearance, according to this parameter of MCC. HTS + TTX also had a significantly greater 
number of minimally mobile particles when compared with HTS. Therefore, not only is the 
nervous system important for causing mucus and the associated particles to travel long distances, 
but it is also important in initiating particle movement. 
 
Despite these differences, there was no apparent change in particle speed when HTS was 
preceded by TTX incubation. This finding may indicate that mobile particles behave similarly, but 
the true difference between treatments is in the number of particles being cleared. Overall, the 
experiments performed using TTX allowed us to support our hypothesis that HTS-triggered MCC 
is dependent on the nervous system.  
 
Thus, blocking the neurogenic contribution to HTS treatment inhibits ~50% of treatment-
induced airway fluid secretion (Luan et al., 2019), but completely blocks the HTS-induced increase 
in MCC. These results suggest that the importance of the nervous system plays a larger role in 
HTS treatment than previously thought. One of the limitations of our experimental approach is 
that, since our ex vivo preparations are missing all innervation from the central nervous system, 
the HTS treatment must only recruit the airway intrinsic neural network for its effects. Experiments 
in vivo could help to determine if this trend is still observed with the involvement of the central 
nervous system. Regardless, it is clear that the nervous system can be harnessed to promote mucus 
clearance, and the next step was to investigate whether sensory agonists could be used to potentiate 
the effects of either HTS or ITS on MCC. 
 
3.2.1 Sensory Mechanism 
 
Live swine treated with ITS and capsaicin have been shown to cause a statistically 
significant increase in ASL height when compared with ITS alone, indicating that capsaicin 
triggers ASL production (Luan et al., 2019). The same study found that adding capsaicin to HTS 
treatment did not potentiate the effects of HTS, therefore suggesting that they both may be acting 
on C-fibres (Luan et al., 2019). This finding prompted experiments examining how capsaicin may 
affect MCC through nebulization with either HTS or ITS (Fig. 3-3). We hypothesized that adding 
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capsaicin to HTS may cause a minor improvement in treatment efficacy, and that the addition of 
capsaicin to ITS treatment will cause a substantial increase in clearance when compared to ITS 
alone, while not achieving levels of clearance observed in HTS or HTS + Capsaicin. ITS + 
Capsaicin caused much greater clearance than that produced by ITS alone. Unexpectedly, ITS + 
Capsaicin appears approximately as effective as HTS and HTS + Capsaicin treatment groups (Fig. 
3-3A). Since ITS + capsaicin is promoting airway hydration only through the neural mediated 
sensory pathways, with no contribution from an osmotic effect (Luan et al., 2019; Szallasi, 2001), 
we must conclude that nervous system stimulation produces the same increase in MCC as HTS 
nebulization.  
 
Similar results were obtained when preparations were treated with menthol. Menthol has 
been shown to stimulate transepithelial Cl- secretion in the airways, and has been suggested to 
influence MCC (Chiyotani et al., 1994). Furthermore, aromatic compounds, such as menthol, are 
able to promote mucus clearance in obstructive lung disease (Hasani et al., 2003). Therefore, we 
decided to investigate how menthol might influence MCC when combined with HTS or ITS (Fig. 
3-4). We hypothesized that HTS + Menthol would be equivalent or better than HTS alone in 
promoting MCC, while ITS + Menthol would be less effective than HTS, but more effective than 
ITS.  
 
Our results indicated that ITS + Menthol was, as expected, much more effective than ITS 
alone, while HTS + Menthol did not appear to cause any statistically significant improvements. It 
is surprising that HTS + Menthol does not appear to cause a significant increase in particles cleared 
5 mm when compared with the ITS group. However, it is noteworthy that the n-value is relatively 
small for the HTS + Menthol group (n = 7). The p-value is relatively small, despite being not 
significant, and so further experiments will need to be performed to confirm the validity of this 
finding. It is possible, however, that the combination of menthol and HTS promotes excessive fluid 
secretion, to the point that it abrogates movement. The excised trachea preparation, unlike in vivo, 
is only ~1-1.5 inches in length, and has an end-point where fluid and mucus accumulate over time; 
the accumulation of fluid and mucus may artificially inhibit movement. It is not unreasonable to 
suggest that, in the event of excess fluid, it causes some degree of additional movement inhibition 
when compared other experiments. Despite this finding, we did find that HTS + Menthol caused 
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a significant decrease in the number of minimally mobile particles (Fig. 3-4B), with values similar 
to those of ITS + Menthol and HTS. What this indicates is that HTS + Menthol is roughly equal 
to HTS and ITS + Menthol in its capacity to induce particle movement, which is, in itself, an 
important indicator of treatment efficacy. Interestingly, ITS + Menthol was able to reproduce the 
effects of HTS, and to a greater level of significance. Similar to our results with capsaicin, the 
effect of ITS + Menthol indicate that stimulation of the sensory neurons is sufficient to replicate 
the effect of HTS, highlighting the importance of the nervous system in MCC. It is also important 
to consider, however, that menthol may also stimulate ciliary beat frequency (Neher et al., 2008). 
This makes it difficult to determine the origin of menthol’s MCC-promoting effects, but it is likely 
a combination of fluid secretions and heightened ciliary beat frequency. Regardless of the 
mechanism, these findings could have exciting implications for treatment of CF-related airway 
disease.  
 
 Taken together, our results indicate that the nervous system plays a major role in 
regulating MCC and airway hydration, and thus it may be an ideal target to produce novel or 
improved therapies. Modulators of the nervous system may be used to increase the duration and 
intensity of HTS-trigger rehydration of the airway and to improve MCC, while reducing the 














CHAPTER 4: THE CONTRIBUTION OF THE NERVOUS SYSTEM TO HTS-
TRIGGERED INCREASE IN MUCOCILIARY CLEARANCE IN CYSTIC FIBROSIS 
SWINE  
 
 Hypertonic saline nebulization is regularly used in patients with cystic fibrosis to improve 
the rheological properties of the airway fluid and increase mucociliary clearance. Thus, we decided 
to study whether the HTS-triggered increase in mucociliary clearance is dependent on the nervous 
system in CF models, as we have described in wild-type swine (Chapter 3). We investigated the 
relationship between HTS and the nervous system in two CF models: transgenic CFTR knockout 
(CFTR-/-) swine, as well as wild-type swine trachea preparations treated with the CFTR blocker, 
CFTRinh-172. While the use of CFTR blockers to model CF provides a simple method to study 
the contribution of CFTR to CF phenotype, the CFTR-/- swine model is a much more powerful 
model. CFTR-/- swine have demonstrated similar disease progression to that of human CF patients, 
including lung pathogenesis. Moreover, CFTR -/- pigs possess a reduced ability to protect against 
pathogens, as well as a higher incidence of lung infections, comparable to what is observed in 
humans (Stoltz et al., 2010). Lastly, CFTR -/- swine exhibit airway mucus buildup, bacterial 
infection, inflammation, and obstruction within the first few months of life (Ostedgaard et al., 
2011; Stoltz et al., 2010). 
  
While it is clear that HTS-triggered increases in MCC is dependent on the nervous system 
in wild-type swine (see Chapter 3 above), it is not immediately clear that the same would be true 
in CF airways. The lack of functional CFTR may affect neural function (since CFTR is expressed 
in sensory neurons), fluid secretion, and cilia movement.  Thus, this chapter of the dissertation will 
focus on experiments performed in the two aforementioned models of CF, as well as their controls.   
 
The initial step of this series of experiments was to test the effect of blocking CFTR in 5-
week-old wild-type animals using the blocker CFTRinh-172, allowing for direct comparisons with 







4.1.1 Blocking CFTR in Wild-Type Swine Does Not Affect HTS-Triggered MCC 
 
CFTRinh-172 is a molecule used to pharmacologically inhibit the CFTR channel (Caci et 
al., 2008), without affecting non-CFTR chloride channels (Ma et al., 2002). The rationale behind 
using this drug is that it provided us with a relatively inexpensive method for modeling CF 
conditions in wild-type pigs. We hypothesized that HTS nebulization will increase MCC in 
CFTRinh-172-treated preparations. Further, we expected that this increase would be mediated, at 
least in part, by the nervous system. Thus, we incubated preparations with CFTRinh-172 and 
treatment them with HTS, HTS + TTX, or ITS. 
 
 The HTS treatment group with no CFTRinh172 caused 5.3 ± 0.6 particles to travel 5 mm, 
compared to 4.6 ± 1.2 particles in HTS + CFTRinh-172 preparations, a difference which was not 
significant (Fig. 4-1A; n = 15 for HTS, n = 8 for HTS + CFTRinh172, n = 10 for HTS + TTX + 
CFTRinh172, n = 7 for ITS + CFTRinh172; p > 0.05, one-way ANOVA and Tukey’s HSD 
multiple comparisons). HTS + TTX + CFTRinh-172 showed 2.9 ± 0.7 particles traveling 5 mm, 
but this was not significantly different from the other treatment groups. Lastly, ITS + CFTRinh-
172 had 2.0 ± 0.6 particles travelling 5 mm, which was significantly less than HTS alone (Fig. 4-
1A, p < 0.05, one-way ANOVA and Tukey’s HSD multiple comparisons).  
 
 HTS treated preparations had a statistically significant reduction in minimally mobile 
particles when compared with ITS + CFTRinh-172 (Fig. 4-1B; p < 0.05, one-way ANOVA and 
Tukey’s HSD multiple comparisons), but no other statistically significant differences were 
observed. Lastly, no statistically significant differences were observed in mean maximum particle 
speed between these groups (Fig. 4-1C, p > 0.05, one-way ANOVA). Further experiments are 
planned to increase the sample sizes between the groups.  
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Figure 4-1. MCC in excised wild-type 5-week-old swine trachea preparations incubated with 












































































































































7 swine, HTS + TTX + CFTRinh-172, n = 10 from 10 swine; ITS + CFTRinh-172, n = 7 from 7 
swine). A) Average number of particles that travelled a minimum of 5 mm in the 20-minute imaging 
interval. HTS showed a statistically significant increase in particles travelling 5 mm over ITS + 
CFTRinh-172, whereby q (36) = 3.975, p = 0.0380. No other statistically significant differences 
were observed. B) Minimally mobile particles between the treatment groups. HTS showed a 
statistically significant reduction in minimally mobile particles when compared with ITS + 
CFTRinh-172, whereby q (35) = 4.104, p = 0.0309. No other statistically significant differences 
were observed. C) Mean maximum speed of each treatment group. No statistically significant 
differences in maximum speed were observed between treatment groups. Results are reported as 
mean ± SEM. Statistics for all figures were calculating using a simple one-way ANOVA and 
Tukey’s HSD post-hoc multiple comparisons where necessary. For all analyses, the assumption of 
homogeneity of variance was met, as determined by Bartlett’s test. Significance level was set at p 
< 0.05.  
 
4.1.2 Blocking Neuronal Function Improves the Effects of HTS Nebulization on MCC in CFTR-/- 
Piglets 
 
The trachea of 1- to 7-day-old male CFTR-/- swine were dissected and used to study the 
effect of HTS on MCC. Each CFTR-/- trachea was divided into two sections, with one portion 
receiving HTS alone, and the other receiving HTS + TTX treatment. The two experimental groups 
were then compared in each piglet using a paired Student’s t-test. As explained in the method 
section, we determined a maximum distance travelled for each pig, and each particle from both 
trachea sections from that pig were then compared, as a percentage, to that maximum distance. 
This modified parameter still measures the ability of a treatment to cause MCC over relatively 
long distances, but normalizes each pig to itself, helping to account for substantial heterogeneity 
observed between pigs in health status and their response to treatment. A higher average 
percentage indicates greater levels of MCC. 
 
The results show that the average percentage of maximal distance travelled in HTS-treated 
preparations was 17.7% ± 6.3%, while in preparations treated with HTS + TTX the particles 
travelled significantly farther, at 46.4% ± 8.7% (Fig 4-2A; n = 4 pigs; p < 0.05, paired t-test). 
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Therefore, it appears that the partial neural block induced by TTX actually improves HTS-
mediated MCC in CFTR-/- piglets. Disaggregating the data into the response by each piglet shows 
that all preparations show the same trend, but with piglet 5 and piglet 6 having statistically 
significantly differences (Fig. 4-2B; p < 0.05, multiple paired t-tests). No statistically significant 









Figure 4-2. Mucociliary clearance in ex vivo swine trachea preparations following treatment with 
HTS or HTS + TTX.  A) Average percentage of maximum distance travelled in CFTR -/- piglets 
(HTS, n = 4 trachea sections from 4 swine; HTS + TTX, n = 4 trachea sections from 4 swine). It 
was found that there is a statistically significant increase in percentage of maximum clearance in 
HTS + TTX when compared with HTS, whereby t (3) = 3.313, p = 0.0453. Statistics were 
calculated using a paired t-test. B) Average percentage of maximum distance travelled for each 








































































































individual piglet. Pig 5 and pig 6 showed a statistically significantly higher clearance in the HTS 
+ TTX treatment groups. Statistics were calculated using multiple paired t-tests. C) and D) 
Average number of particles travelling 5 mm in 1-week-old and 1-day-old controls, respectively. 
In C, HTS (n = 13 trachea sections, from 13 swine) showed no statistically significant difference 
from HTS + TTX (n = 7 trachea sections from 7 swine). In D, HTS (n = 5 trachea sections from 5 
swine) showed no statistically significant difference from HTS + TTX (n = 5 from 5 swine). 
Statistics were calculated using an unpaired t-test, with the addition of Welch’s correction for 
unequal variances in C only. Results are reported as mean ± SEM. Significance level was set at p 
= 0.05. 
 
 Comparing the average number of particles travelling at least 5 mm between HTS and HTS 
+ TTX in 1-week-old wild-type controls, HTS showed 7.0 ± 0.4 particles travelling 5 mm, while 
HTS + TTX showed 5.6 ± 1.1 particles. No statistically significant difference was observed 
between the HTS and HTS + TTX treatment groups (Fig. 4-2C; n = 13 for HTS, n = 7 for 
HTS+TTX;  p > 0.05, Welch’s unpaired t-test). Similarly, we compared these treatments in 1-day- 
old piglets (Fig. 4-2D). HTS showed a 6.6 ± 1.2 particles travelling 5mm, while HTS + TTX 
showed 6.0 ± 1.3 particles. No statistically significant difference was observed between the two 
groups (Fig. 4-2D; n = 5 for HTS, n= 5 for HTS + TTX; p > 0.05, unpaired t-test). Therefore, it 
appears that there is no statistically significant difference in the number of particles travelling 5 






Figure 4-3. Mean maximum particle speed in ex vivo swine trachea preparations following 
nebulization treatment.  A) CFTR-/- piglets treated with either HTS (n = 2 trachea sections from 
2 swine) or HTS + TTX (n = 2 from 2 swine). There was no statistically significant difference 
observed between HTS and HTS + TTX. Statistics were performed using a paired t-test. B) break 
down of the paired t-test from A into individual comparisons. In pig 5, HTS + TTX appears to have 
a statistically significantly higher mean maximum particle speed when compared with HTS, 
whereby t (14) = 3.099, p = 0.0156. C) and D) compare HTS with HTS + TTX in wild-type 1-
week-old and 1-day-old piglets, respectively. No statistically significant differences were observed 

























































































between HTS (n = 13 from 13 swine) and HTS + TTX (n = 7 from 7 swine) in 1-week-old swine. 
No statistically significant differences were observed between HTS (n = 5 from 5 swine) and HTS 
+ TTX (n = 5 from 5 swine) in 1-day-old piglets. Statistics for C and D were calculated using an 
unpaired t-test, as well as an F-test to ensure equal variances. Results for each figure are reported 
as mean ± SEM. Significance level was set at p = 0.05. 
 
 Mean maximum particle speed was calculated and compared between HTS and HTS + 
TTX treatment groups in CFTR-/- swine, as well as wild-type 1-week- and 1-day-old controls. 
Only two CFTR-/- swine met the criteria to be included in this analysis. In CFTR-/- swine, there 
was no apparent effect on neural block on mean maximum particle speed (Fig. 4-3A; p > 0.05, 
paired t-test). HTS (n = 2) had a mean maximum particle speed of 1.6 ± 1.1 mm/min, while HTS 
+ TTX (n = 2) was shown to have 3.3 ± 2.2 mm/min. Figure 4-3B breaks down the comparison to 
show individual paired t-tests performed for each pig. Here, it can be seen that in pig 5, HTS + 
TTX group had a statistically significant increase in mean maximum particle speed when 
compared with HTS (Fig. 4-3B; p < 0.05, paired t-test). The small sample size of this analysis 
makes it difficult to draw any conclusions, but I will defer to the lack of statistically significant 
difference observed in 4-3A. Figure 4-3C and 4-3D compare the mean maximum particle speed of 
wild-type controls, using 1-week- and 1-day-old pigs respectively. No statistically significant 
difference was observed in either comparison (Fig. 4-3C and Fig. 4-3D; p > 0.05, unpaired t-test), 





Figure 4-4. Mean number of tantalum particles minimally mobile during imaging of ex vivo swine 
trachea preparations. A) compares HTS (n = 4 trachea preparations from 4 swine) and HTS + 
TTX (n = 4 from 4 swine) treatment groups in CFTR-/- pigs. No statistically significant difference 
was observed between HTS and HTS + TTX groups. Statistics were calculated using a paired t-
test. B) and C) show control experiments comparing HTS and HTS + TTX groups in wild-type 1-
week-old and 1-day-old swine, respectively. No statistically significant difference was observed 
between HTS (n = 13 from 13 swine) or HTS + TTX (n = 7 from 7 swine) in B. Statistics for B 
were calculated using an unpaired t-test with Welch’s correction for unequal variances. No 
statistically significant difference was observed between HTS (n = 5 from 5 swine) and HTS + 
TTX (n = 5 from 5 swine) in C. Statistics for C were calculated using an ordinary unpaired t-test, 
with an F-test to ensure equality of variances. Results are reported as mean ± SEM. Significance 




































































 Figure 4-4A compares HTS and HTS + TTX treatment groups in CFTR-/- swine. HTS was 
shown to have 4.6 ± 2.0 particles that were minimally mobile, while HTS + TTX showed 3.1 ± 1.2 
minimally mobile particles. This was not a statistically significant difference (Fig. 4-4A; n = 4 for 
HTS and HTS+TTX; p > 0.05, paired t-test). In wild-type 1-week-old controls, HTS had  0.3 ± 0.2 
particles minimally mobile, while HTS + TTX showed 1.4 ± 0.9 particles, which was not a 
statistically significant difference (Fig. 4-4B; n = 13 for HTS, n = 7 for HTS + TTX; p > 0.05, 
unpaired t-test with Welch’s correction for unequal variances). Lastly, in wild-type 1-day-old 
piglets, the number of minimally mobile particles was not statistically significant between HTS 
and HTS + TTX-treated preparations (Fig. 4-4C; n = 5 for HTS and HTS + TTX; p > 0.05, unpaired 
t-test). Therefore, no statistically significant differences were observed in either wild-type or 
CFTR-/- piglets. 
 
4.3 Discussion  
 
 The most salient result was the surprising effect of TTX on CFTR-/- swine preparations. 
While blocking the nervous system reduces the HTS-triggered ASL production (Luan et al. 2019), 
and completely blocks HTS-induced increases in MCC in wild-type swine (Chapter 3), CFTR-/- 
preparations actually displayed an increase in HTS-induced increase in MCC after blocking the 
nervous system. More work would be needed to fully understand the reasons behind improved 
MCC after blocking the nervous system in CF; however, there are some indications of how this 
may work in the literature. One study has shown that impaired mucociliary transport in CF airways 
may be a result of CF submucosal glands secreting mucus strands that fail to detach from the gland 
ducts, thereby inhibiting MCC (Hoegger et al., 2014). HTS nebulization may act on the CF airway 
by improving the hydration of the airway and rheological properties of the mucus, which results 
in improved lung function (Donaldson et al., 2006). However, if mucus strands secreted by 
submucosal glands fail to detach from the submucosal glands, then it is possible that neural 
stimulation of submucosal gland secretions via HTS may actually have a counterproductive effect 
on MCC through this pathway. Thus, blocking the neurogenic response inhibits glandular secretion 
and leads to a decrease in mucus tethering to the glands. By partially blocking the neural 
component of this interaction via TTX, there would be less neural stimulation of submucosal gland 
secretions via these sensory networks. Instead, HTS would be, in the presence of TTX, relying 
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more heavily on an osmotically driven transepithelial secretion of fluid. While overall changes in 
ASL height may be reduced when compared to HTS alone, it would also potentially result in a 
reduction in tethered mucus strands (Hoegger et al., 2014) that fail to detach. This may also explain 
the finding that there is no significant difference in the number of minimally mobile particles 
between HTS and HTS + TTX (Fig. 4-4A). Impaired mucus detachment from the submucosal 
glands (Hoegger et al., 2014) may not influence the ability of mucus and particles to travel small 
distances. The relatively small distance of 1 mm may be achieved reasonably well in both HTS 
and HTS + TTX treatment conditions (i.e., even when there are more tethered mucus strands), but 
the real difference resides in their respective abilities to promote MCC over longer distances. These 
unforeseen findings may suggest that the neural component of HTS treatment in CF conditions 
could actually be preventing HTS from achieving its full potential in promoting MCC. Additional 
studies using varied methods will be necessary to further characterize this relationship. 
 
The results obtained from wild-type swine treated with CFTRinh-172 were fundamentally 
different from those observed in CFTR-/- swine. Our data seems to indicate that there are no 
significant differences in the overall clearance, or speed of clearance, between tissues treated with 
just HTS, and those treated with CFTRinh-172 or CFTRinh-172 and TTX. These results are 
different from those in 5-week-old animals (Chapter 3), where TTX reduces MCC. It was 
surprising to see that there was no difference between HTS and HTS + TTX in 1- and 7-day-old 
animals. It is possible that, at this young age in healthy animals, MCC is already occurring 
optimally, such that addition of HTS has no significant effect on further improving MCC, and thus 
there would be no effect of TTX on reducing MCC. However, this result may also be an artifact 
of the experimental set up.  It is possible that the methods employed for incubation with CFTRinh-
172 may not have allowed it to properly penetrate the mucosa, thereby preventing access to the 
CFTR channel. Moreover, the sample size for the wild-type preparations incubated with 
CFTRinh172 may be too small. Therefore, to ensure the accurate characterization of this 
relationship, additional experiments have been planned. Regardless of the reason behind the lack 
of significant difference in these wild-type control groups, the result does allow us to conclude that 
the trends observed in CFTR-/- piglets are likely not a product of their age. Overall, these findings 
were unexpected, and are quite different than the results found in the CFTR-/- animals and those 
in Chapter 3. 
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CHAPTER 5: GENERAL CONCLUSION 
 
 The nervous system does, in fact, play a role in HTS-mediated changes in MCC. In wild-
type swine, blocking the nervous system via preincubation with TTX essentially removed the 
effects that HTS has on mucociliary clearance. While we expected there to be some reduction in 
MCC in response to TTX, we did not expect HTS to lose, essentially, the entirety of its effects. 
This finding suggests that, despite HTS causing a significant increase in ASL height when the 
nervous system is blocked in comparison to ITS (Luan et al., 2019), there may be complete absence 
of the treatment’s effects on MCC without the neural component.  
 
Our CFTR-/- results showed that blocking the neurogenic response to HTS actually 
improved HTS-induced increases in MCC. This finding was entirely unexpected, refuting all of 
our prior hypotheses that blocking the nervous system would attenuate the response to HTS. While 
the reasoning for this behaviour remains somewhat uncertain, one possible explanation for this 
finding is that HTS stimulates submucosal gland secretions which, in CF airways, may fail to 
detach from the glands (Hoegger et al., 2014). By failing to detach, the mucus strands may enable 
clearance of particles over short distances, followed by failure to continue travelling. This is 
supported by the finding that, despite HTS + TTX showing a higher average percentage of 
maximal movement when compared to HTS alone (Fig. 4-2A), they demonstrated similar numbers 
of minimally mobile particles (Fig. 4-3A). This could be interpreted as both treatments having 
approximately the same propensity to induce movement, but preincubation with TTX allows for 
the particles, and thus the mucus, to travel longer distances. By blocking the nervous system, we 
suggest that there is only the osmotic fluid secretion, and a reduction in the prevalence of mucus 
strands that inhibit more distant movement. 
 
5.1 Significance for the Development of New Treatments  
 
  Currently, in the year 2020, there is ongoing interest in developing an airway rehydration 
therapy superior to HTS, such as ENaC blockers to inhibit airway surface liquid reabsorption 
(clinical trials for Parion PS-G201; Boehringer Ingelheim BI1265162; AstraZeneca AZD5643; 
Novartis QBW276). There is also interest in increasing tolerability and effectiveness by replacing 
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HTS with mannitol or hypertonic xylitol (Singh et al., 2020) (clinical trial registration 
NCT00928135), or adding hyaluronic acid to HTS formulation to increase “pleasantness” (Máiz 
et al., 2018). However, there are no treatments under development that exploit the contribution of 
the nervous system to MCC.   
 
  Our results could have interesting implications for HTS treatment of CF lung disease as 
well as non-CF bronchiectasis. We show that the nervous system is a major contributor to 
improved MCC after HTS nebulization in non-CF tissues. Addition of capsaicin or menthol to 
HTS formulation does not seem to further increase the rate of MCC, according to our results; 
however, it may have a large benefit on the duration of the treatment. Luan et al. (2019) showed 
that adding capsaicin or menthol to the HTS formulation increased the duration of the nebulized 
treatment. HTS alone produced an increase in hydration for 90 min, while adding capsaicin or 
menthol extended the effect to 4 hours. Thus, even though we did not measure an increase in MCC 
in the timeframe of our experiments (~20 min), it is possible that adding capsaicin or menthol may 
result in an increased MCC for a longer period of time after nebulization.   
 
 Addition of sensory agonists may have negative effects on the patients by inducing cough, 
though this may assist in the clearance of mucus. It is important to consider that increased coughing 
may make it a less tolerable treatment for certain patients. We also saw that menthol clearly has a 
beneficial effect on MCC when combined with ITS, and may be equivalent to HTS alone when 
combined with HTS. While some patients struggle to tolerate HTS due to its emergency reflex 
responses, such as coughing, epiglottal closure, and airway constriction (Wine, 2007), menthol has 
actually been shown to increase cough reflex threshold (Wise et al., 2012). ITS appears to be 
harmless (Driessen et al., 2013), and if it does not cause these unwanted effects, it is possible that 
using ITS to deliver nebulized menthol could be a valid alternative to HTS treatment for CF and 
non-CF related lung disease. Additionally, while HTS causes unwanted neurogenic inflammation 
(Umeno et al., 1990; Wine, 2007), menthol has been shown to have counter-irritant effects, thereby 
reducing neurogenic inflammation (Andersen et al., 2016). Through its counter-irritant and cough-
suppressant effects, the presence of menthol may make HTS more tolerable in certain patients, 
thereby helping patient adherence and improving lung health in the process. The highly tolerable 
nature of menthol and the potential for its effects on airway secretions (Chiyotani et al., 1994) and 
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MCC make it a strong candidate for improving upon HTS as an airway rehydration treatment in 
CF and the treatment of non-CF bronchiectasis.  Thus, further work needs to be done to formulate 
a combination of HTS and sensory agonists that may be well-tolerated by live animals, as well as 
humans, for future research and drug development. Lastly, because we observed the neurogenic 
response to HTS to be inhibitory of movement in CFTR-/- swine, it would be necessary to perform 
experiments using sensory agonists in a CF model before any suggestions can be made about its 
efficacy in treating CF-related lung disease.  
 
 Overall, the nervous system is clearly a powerful entity in regulating MCC, and plays a 
substantial role in this commonly used treatment for CF-related lung disease. By understanding 
how HTS functions to improve lung health and promote MCC, we may find methods of harnessing 
the nervous system in such a way that enhances the effects of existing treatments, or replaces them 
altogether. While this study is limited to making inferences about CF and non-CF swine, it 
provides valuable insight that will direct future inquiries into this treatment strategy, as well as the 
nervous system as it relates to CF. A great deal remains to be discovered about this complex 
system, but it is clear that an enhanced understanding of nervous system’s role in mediating 
mucociliary clearance in the context of HTS certainly has the potential to improve the health of 
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APPENDIX: DEVELOPMENT OF THE MUCOCILIARY CLEARANCE ASSAY  
 
 CF respiratory pathogenesis largely stems from impaired MCC resulting from impaired ion 
transport (Donaldson et al., 2007). Modulating rheological properties of mucus and promoting 
clearance has been a common theme in treatment (Robinson & Bye, 2002), including HTS. 
Experiments that model MCC have great potential in understanding the impaired clearance in CF 
patients, as well as the effects of treatments. While techniques exist to measure MCC, there has 
been limited success in detecting a difference between CF and non-CF patients (Robinson et al., 
2000; Robinson & Bye, 2002). Recently, ex vivo techniques have been developed, whereby 
radiodense tantalum microdisks were placed on sections of trachea and monitored over time 
(Hoegger et al., 2014). Using these ex vivo MCC techniques, it was concluded that impaired 
mucociliary transport (MCT) was, as expected, a primary defect in CF patients. They went on to 
suggest that the loss of CFTR channels in submucosal glands may be the reason for failed mucus 
detachment from these glands, thus causing impaired MCT (Hoegger et al., 2014). With other 
studies reporting evidence that airway surface dehydration may initiate CF respiratory 
pathogenesis (Boucher, 2007), our lab sought to develop a MCC assay that could be used to study 
airway rehydration treatments, such as HTS, and their effects on MCC.  
 
 Beginning in September of 2018, the initial goal of the project was to develop an assay that 
could effectively show MCC, while being sensitive enough to also detect changes in MCC between 
treatment groups. Previous iterations prior to my tenure in the lab had limited success, but their 
work contributed substantially to the success had with my experiments. The assay we developed 
is partially based off an assay used by the Hoegger lab (Hoegger et al., 2014). They developed a 
technique whereby mucociliary transport (MCT) was tracked using radiodense 350 μm diameter 
tantalum microdisks, with X-ray computed tomography used to measure movement of the disks. 
We adopted the use of tantalum for the particles, first beginning with tantalum powder. The benefit 
of the powder was that there were particles substantially smaller than 350 μm, representing a more 
physiological context for particle clearance; it is rare that particles of that size are cleared via MCC, 
with most inhaled particles and pathogens being significantly smaller (Thomas, 2013). Preliminary 
experiments prior to my work in the lab demonstrated limited clearance of the powder. One 
possible explanation for this is that the powder frequently aggregated, creating clumps of material 
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much larger than the 350 μm disks employed by Hoegger. This led to us adopting the use of 
microdisks. Using a micro-hole puncher we produced tantalum microdisks with a diameter of 250 
μm, and a thickness of 25 μm. While still larger than most inhaled particles, it was a major step in 
creating a functional assay and is a definite advantage over other existing ex vivo MCC assays. 
This was the first of the key differences that made our assay preferable to the experimental 
questions we wanted to answer.  
 
 A second major difference between our methods and those described by Hoegger is that 
they used saline to submerge the luminal surface of the trachea during imaging (Hoegger et al., 
2014). For our objectives and goals, this method was problematic. Foremost, the use of saline to 
submerge the trachea during imaging would wash out the effects of any treatment applied to the 
airway and it would make it impossible to nebulize the lumen of the airway. HTS has previously 
been shown to cause an increase in the height of the ASL (Luan et al., 2019); therefore, the addition 
of fluid to the surface after nebulization would essentially negate the benefits of HTS, and equalize 
fluid heights between treatment groups. We were interested in determining if this increase in ASL 
height could be responsible for the improved clearance caused by HTS and, to do so, we needed 
an assay that kept the luminal surface of the trachea relatively clear of exogenous fluid after the 
initial wash with phosphate buffer solution (PBS). Though PBS itself could have an effect on 
clearance, we observed minimal residual fluid by the time imaging was occurring ~25 minutes 
later. Additionally, the PBS wash occurred prior to nebulization, creating a standardized starting 
point that provides a clearer picture of the effects of a treatment on MCC. The goal of preventing 
fluid from entering the lumen created a problem for treating the tissue with drugs such as CFTRinh-
172 and TTX. With the lumen clamped off to prevent fluid entry, and the cartilage protecting the 
outer-surface of the mucosa, we realized the need to dissect the cartilage. Our assay is unique in 
that it involves removal of a portion of the cartilage to allow for pharmacological agents to reach 
the mucosal layer from the outside. This allowed us to overcome the challenge of treating the tissue 






Cleaning the Trachea 
 
 One of the major challenges that had to be overcome during the development of this 
technique was the cleaning of the lumen of the trachea prior to experimentation. There was 
considerable heterogeneity between different animals, as well as separate preparations of the same 
animal, in the amount of blood, fluid, and other unwanted matter in the trachea. Having 
inconsistent baseline fluid levels, or the presence of material or fluid that could potentially abrogate 
particle movement or irritate the trachea to cause fluid secretions, was a confounding effect that 
had to be eliminated. The initial method used to clean the tissue was sterile medical gauze 
bandages. This was somewhat effective in removing blood and other fluid that entered the airways 
during the euthanasia of the animal; however, it was soon observed that particles displayed 
minimal movement, likely as a result of epithelial damage. The delicate nature of the epithelium 
and its cilia meant that tactile force without fine control would cause damage that could not be 
standardized between experiments. The more cleaning a trachea needed, the more damage that 
would result from cleaning. This led to the use of sterile Q-tips to give greater control in cleaning. 
The Q-tip was used to spot-clean areas with high prevalence of blood or other matter. This method 
was more effective than gauze in cleaning the preparation, but once again, compared to tissues that 
lacked cleaning, these preparations did not exhibit as much clearance. We concluded that this was 
likely the result of damage to the epithelium from excessive force. The realization was that the 
trachea had to be cleaned without physically touching the surface with a cleaning object. The use 
of PBS was suggested, whereby trachea would be repeatedly dunked in PBS to remove blood, 
foam, and other contaminants. This method was found to be effective in cleaning the airway 
without causing damage to the epithelium. 
 
Future Directions with the Assay  
 
 My work in developing the assay was from September-November 2018, but previous 
students had spent significant time (~2 years) working on the assay and making contributions that 
allowed me to achieve success with it. Their work was just as important in getting the assay to its 
current functional state. I expect my work and ideas will similarly help further improve and iterate 
upon this technique, with the following plans in progress: 
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The use of labelled bacteria, such as GDP-labelled Pseudomonas aeruginosa, will 
hopefully be used in future iterations of this assay. As mentioned, the tantalum disks used are 
relatively large compared to the actual size of inhaled particles and pathogens (Barbara H. 
Iglewski, 1996). In CF, chronic respiratory tract infections, including those of Pseudomonas 
aeruginosa (Speert et al., 2002), are relevant to health outcomes; therefore, improving this assay 
to measure movement of bacteria could provide valuable information about how treatments may 
improve clearance of these pathogens. Some have suggested that there could be differential 
movement of microscopic particles, including pathogens, compared to more macroscopic 
particles, such as the microdisks we currently employ, but this has yet to be explored. The use of 
fluorescent microscope-based imaging and fluorescing bacteria could provide valuable 
information regarding the potential differential clearance of small versus large particles. It has 
been suggested that the mucus strands play a role in adhering to and dragging macroscopic 
particles, with the underlying ASL being more involved in the transport of pathogens and other 
microscopic particles.  
 
 
 
 
 
 
 
 
 
  
